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SCIENTIFIC OPINION 
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(DPA)
1 
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2, 3 
European Food Safety Authority (EFSA), Parma, Italy 
ABSTRACT 
Following a request from the European Commission, the Panel on Dietetic Products, Nutrition and Allergies was 
asked  to  deliver  a  scientific  opinion  on  the  Tolerable  Upper  Intake  Level  (UL)  of  the  n-3  LCPUFAs 
eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA) and docosapentaenoic acid (DPA). Available data 
are insufficient to establish a UL for n-3 LCPUFA (individually or combined) for any population group. At 
observed intake levels, consumption of n-3 LCPUFA has not been associated with adverse effects in healthy 
children or adults. Long-term supplemental intakes of EPA and DHA combined up to about 5 g/day do not 
appear  to  increase  the  risk  of  spontaneous  bleeding  episodes  or  bleeding  complications,  or  affect  glucose 
homeostasis immune function or lipid peroxidation, provided the oxidative stability of the n-3 LCPUFAs is 
guaranteed. Supplemental intakes of EPA and DHA combined at doses of 2-6 g/day, and of DHA at doses of 
2-4 g/day, induce an increase in LDL-cholesterol concentrations of about 3 % which may not have an adverse 
effect on cardiovascular disease risk, whereas EPA at doses up to 4 g/day has no significant effect on LDL 
cholesterol. Supplemental intakes of EPA and DHA combined at doses up to 5 g/day, and supplemental intakes 
of EPA alone up to 1.8 g/day, do not raise safety concerns for adults. Dietary recommendations for EPA and 
DHA  based  on  cardiovascular  risk  considerations  for  European  adults  are  between  250  and  500 mg/day. 
Supplemental intakes of DHA alone up to about 1 g/day do not raise safety concerns for the general population. 
No data are available for DPA when consumed alone. In the majority of the human studies considered, fish oils, 
also containing DPA in generally unknown (but relatively low) amounts, were the source of EPA and DHA. 
© European Food Safety Authority, 2012. 
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SUMMARY 
Following a request from the European Commission, the Panel on Dietetic Products, Nutrition and 
Allergies  was  asked  to  deliver  a  scientific  opinion  on  the  Tolerable  Upper  Intake  Level  of 
eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA) and docosapentaenoic acid (DPA). 
Omega-3 (n-3) polyunsaturated fatty acids (PUFAs) contain one of the double bonds located at three 
carbon  atoms  from  the  methyl  end.  The  main  n-3  PUFAs  in  the  diet  are  -linoleic  acid  (ALA; 
18:3Δ9c,12c,15c),  eicosapentaenoic  acid  (EPA;  20:5Δ5c,8c,11c,14c,17c),  docosahexaenoic  acid 
(DHA; 22:6Δ4c,7c,10c,13c,16c,19c ) and docosapentaenoic acid (DPA; 22:5Δ7c,10c,13c,16c,19c). 
EPA, DHA and DPA are n-3 long-chain PUFAs (n-3 LCPUFA), i.e. n-3 PUFA with 20 or more 
carbon  atoms.  The  n-3  LCPUFAs  are  important  structural  components  of  cell  membranes  and 
contribute to various membrane functions such as fluidity, permeability, activity of membrane-bound 
enzymes and receptors, and signal transduction. 
Fish is a uniquely rich source of n-3 LCPUFAs. Other natural sources are human milk, cultivated 
marine algae, marine mammals and krill. EPA, DHA and DPA may also be provided by foods and 
supplements enriched with n-3 LCPUFAs (e.g. fish oils, single cell oils, krill oils added to foods or 
consumed as food supplements). The ratios of EPA:DHA:DPA differ between the various sources of 
n-3 LCPUFAs, although DPA is generally a minor quantitative component compared to EPA and 
DHA. Food supplements containing mainly EPA, or mainly DHA (isolated from microalgae), are also 
available. Pure DPA is not commercialised for human consumption. 
Adverse effects, which have been described in humans in association with high intakes of EPA and 
DHA,  include  bleeding  episodes,  impaired  immune  function,  increased  lipid  peroxidation,  and 
impaired lipid and glucose metabolism. However, no tolerable upper intake level (UL) for EPA, DHA 
or DPA has been set by any authoritative body. 
Previous assessments on the safety of n-LCPUFAs referred to mixtures of EPA and DHA (DPA was 
not explicitly mentioned), and were primarily based on a large number of human studies. The Panel 
considers that the evaluation of the safety of n-3 LCPUFA intakes should be based on the human 
studies available.  
The majority of human intervention studies which have investigated the effects of n-3 LCPUFAs on 
different  health  outcomes  have  used  fish  oils  containing  known  amounts  of  EPA  and  DHA  and 
generally unknown (but relatively low) amounts of DPA; EPA and DHA in combination as ethyl 
esters; or more rarely mostly EPA or mostly DHA. Very few studies are available using krill oil as a 
source of EPA and DHA, and no studies have been conducted with sources containing mainly DPA, 
or with DPA alone. 
Long-term human intervention studies which have investigated the effects of supplemental intakes of 
EPA and DHA, either alone or in combination, at doses up to about 1 g/day on a variety of health 
outcomes  (e.g.,  cardiovascular,  neurological,  immunological),  have  generally reported no adverse 
effects in relation to the consumption of EPA or DHA at these doses. 
Long-term supplemental intakes of EPA and DHA combined up to about 5 g/day do not increase the 
risk of spontaneous bleeding episodes or bleeding complications  even in subjects at high risk of 
bleeding (e.g. taking acetylsalicylic acid or anti-coagulants).  
Supplemental  intakes  of  EPA  and  DHA  combined  at  doses  up  to  5 g/day  consumed  for  up  to 
12 weeks do not significantly affect glucose homeostasis in healthy or diabetic subjects, nor do they 
induce changes in immune functions which might raise concern in relation to the risk of infections or 
inappropriate activation of inflammatory responses. The data available are insufficient to conclude on Tolerable Upper Intake Level of EPA, DHA and DPA 
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whether the same doses administered mostly as EPA or mostly as DHA would have different effects 
on these outcomes.  
Supplemental intakes of EPA and DHA consumed either alone or in combination at doses up to about 
5 g/day for up to 16 weeks do not induce changes in lipid peroxidation which might raise concern in 
relation to cardiovascular disease (CVD) risk as long as the oxidative stability of these n-3 LCPUFA 
is guaranteed.    
Supplemental intakes of EPA and DHA combined of 2-6 g/day, and supplemental intakes of mostly 
DHA of 2-4 g/day, increase blood concentrations of LDL cholesterol by about 3 %. Such increase is 
accompanied  by  a  decrease  in  triglycerides  with  no  changes  in  total  (or  non-HDL)  cholesterol 
concentrations. Supplemental intakes of mostly EPA at doses up to 4 g/day have no significant effect 
on LDL-cholesterol concentrations. The Panel considers that the small increase in LDL-cholesterol 
concentrations  associated  with  combined  EPA  and  DHA  supplementation  or  with  DHA 
supplementation alone at the doses mentioned above may not have an adverse effect on CVD risk.  
The Panel concludes that the available data are not sufficient to establish a tolerable upper intake 
level for n-3 LCPUFA (DHA, EPA, and DPA, individually or combined) for any population group. 
At observed intake levels, consumption of n-3 LCPUFA has not been associated with adverse effects 
in healthy children or adults.  
The Panel considers that supplemental intakes of EPA and DHA combined at doses up to 5 g/day, 
and supplemental intakes of EPA alone up to 1.8 g/day, do not raise safety concerns for the adult 
population. Limited data are available on the effects of long-term supplementation with these n-3 
LCPUFAs at higher doses. The Panel also notes that observed intakes of EPA and DHA from food 
and  food  supplements  in  European  populations  are  generally  below  these  amounts.  Dietary 
recommendations  for  EPA and DHA based on  CVD risk considerations for European adults are 
between 250 and 500 mg/day. There are no specific recommendations for EPA. 
The Panel also considers that supplemental intakes of DHA alone up to about 1 g/day do not raise 
safety concerns for the general population. Limited data are available on the effects of long-term 
supplementation  with  DHA  alone  at  higher  doses.  The  Panel  notes  that  specific  dietary 
recommendations for DHA for European adults and children are well below this amount.  
No data are available for DPA when consumed alone. The Panel notes that in the majority of the 
human studies considered, fish oils, which also contained DPA in generally unknown (but relatively 
low) amounts, were the source of EPA and DHA. No dietary recommendations have been  made 
specifically for DPA. 
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BACKGROUND AS PROVIDED BY THE EUROPEAN COMMISSION 
Several Member States have raised concerns about a potential link between the intake of omega-3 
long chain polyunsaturated fatty acids (eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), 
docosapentaenoic acid (DPA)) and adverse health effects. 
The scientific opinion of the European Food Safety Authority of 6 July 2005
4 on nutrition claims 
concerning omega-3 fatty acids refers to the reporting of adverse effects of high consumption of 
omega-3 polyunsaturated fatty acids and these effects include prolonged bleeding time and increased 
tendency to nasal bleeding, suppression of certain immune reactions which enable the body to attack 
pathogens and adverse effects on oxidation of LDL cholesterol. 
Scientific opinions of the  European Food  Safety Authority on the substantiation of health claims 
related to EPA and DHA have proposed intakes of EPA and DHA of about  2-4 g/day in order to 
obtain the claimed effects
5. 
In the absence of EU advice on a tolerable upper int ake level, the German Federal Risk Assessment 
Agency has established a level of 1. 5 g/day as the recommended upper intake level for omega -3 
polyunsaturated fatty acids. The US Food and Drug Administration (FDA) has recommended not to 
exceed an intake of 3 g/day of omega-3 fatty acids (EPA and DHA) as a safeguard against possible 
adverse effects of these fatty acids.  
TERMS OF REFERENCE AS PROVIDED BY THE EUROPEAN COMMISSION 
In accordance with Article 29(1)(a) of Regulation (EC) No 178/2002 of the European Parliament and 
of the Council of 29 January 2002 laying down the general principles and requirements of food law, 
establishing the  European Food Safety Authority and laying down procedures in matters of food 
safety
6, the European Commission asks the European Food Safety Authority to: 
Review the existing scientific data on the possible link between the intake of omega -3 long-chain 
polyunsaturated fatty acids (DHA, EPA, DPA) and adverse health effects in the general population 
and, as appropriate in specific vulnerable subgroups of the population. 
Provide advice on a tolerable upper intake level (UL) for omega -3 long-chain polyunsaturated fatty 
acids (DHA, EPA, DPA) individually or combined for the general population and, as appropriate, for 
vulnerable subgroups of the population.  
In the absence of tolerable upper intake level, to provide advice on a daily intake of omega -3 
long-chain polyunsaturated fatty acids (DHA, EPA, DPA) either individually or combined  and which 
does not give rise to concerns about adverse health effects. 
                                                       
4  The EFSA Journal 2005; 253, 1-29.  
5  EFSA Journal 2009; 7(9):1263; EFSA Journal 2010;8(10):1734; EFSA Journal 2010;8(10):1796 
6  OJ. L 31, 1.2.2002, p.1-24. Tolerable Upper Intake Level of EPA, DHA and DPA 
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ASSESSMENT 
1.  Introduction 
Omega-3 (n-3) polyunsaturated fatty acids (PUFAs) contain one of the double bonds located at three 
carbon  atoms  from  the  methyl  end.  The  main  n-3  PUFAs  in  the  diet  are  -linoleic  acid  (ALA; 
18:3Δ9c,12c,15c),  eicosapentaenoic  acid  (EPA;  20:5Δ5c,8c,11c,14c,17c),  docosahexaenoic  acid 
(DHA; 22:6Δ4c,7c,10c,13c,16c,19c ) and docosapentaenoic acid (DPA; 22:5Δ7c,10c,13c,16c,19c). 
The  n-3  PUFAs  EPA,  DHA  and  DPA  are  usually  referred  to  as  n-3  long-chain  PUFAs 
(n-3 LCPUFAs), i.e. n-3 PUFA with 20 or more carbon atoms. The n-3 LCPUFAs are important 
structural  components  of  cell  membranes  and  contribute  to  various  membrane  functions  such  as 
fluidity, permeability, activity of membrane-bound enzymes and receptors, and signal transduction. 
Adverse  effects,  which  have  been  described  in  humans  in  association  with  high  intakes  of  n-3 
LCPUFA, include bleeding episodes, impaired immune function, increased lipid peroxidation, and 
impaired lipid and glucose metabolism. However, no tolerable upper intake level (UL) for EPA, DHA 
or DPA has been set by any authoritative body.  
In 1997, the US Food and Drug Administration (FDA, 1997) concluded that total intakes (from diet 
and supplements) of EPA and DHA up to 3 g/day were generally recognised as safe (GRAS). This 
figure was set on the basis of increased bleeding times, increased fasting blood glucose concentrations 
in non-insulin dependent, type 2 diabetic subjects, and increased LDL-cholesterol concentrations, 
particularly in hypertriglyceridaemic or hypercholesterolaemic subjects, at higher levels of intake.   
In 2004, the FDA approved a mixture of EPA and DHA in the form of ethyl esters as a registered drug 
for the treatment of hypertriglyceridaemia in adult patients at doses of 4 g/day. No significant adverse 
effects were reported for the drug vs. placebo in human intervention studies at this dose.  
In 2005, the US Institute of Medicine (IoM, 2005) also evaluated the safety of n-3 LCPUFA and 
concluded that the available data were insufficient to set a UL for EPA and DHA, although subjects 
with impaired glucose tolerance or type 2 diabetes and subjects with familial hypercholesterolemia 
using anticoagulants were recommended to consume EPA and DHA supplements with caution. The 
bases of this recommendation are not explicitly stated.   
In May 2009, the German Federal Risk Assessment Agency (BfR, 2009) recommended that 1.5 g/day 
of EPA and DHA from all sources should not be exceeded and this recommendation was based on the 
increased risk of bleeding reported in one study in children (Clarke et al., 1990). 
In June 2011, the Norwegian Scientific Committee for Food Safety (VKM, 2011) conducted a safety 
evaluation of n-3 LCPUFA from all sources. Previous evaluations by other authoritative bodies and an 
up to date review of the literature available up to March 2009 were taken into account. No clear 
adverse effects were associated with EPA and DHA intakes up to 6.9 g/day and no UL could be 
established.  
The Panel notes that the conclusions of all these safety assessments referred to mixtures of EPA and 
DHA (DPA was not explicitly mentioned) and were primarily based on a large number of human 
studies.   
The Panel considers that the evaluation of the safety of n-3 LCPUFA intakes should be based on the 
human studies available.  Tolerable Upper Intake Level of EPA, DHA and DPA 
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2.  Nutritional background 
2.1.  Food sources including dietary supplements 
Fish is a uniquely rich source of n-3 LCPUFA (EFSA (European Food Safety Authority), 2005). 
Other natural sources are human milk, cultivated marine algae, marine mammals and krill. EPA, DHA 
and DPA may also be provided by foods and supplements enriched with n-3 LCPUFAs (e.g., fish oils, 
single  cell  oils,  krill  oils  added  to  foods  or  consumed  as  food  supplements).  The  ratios  of 
EPA:DHA:DPA differ between the various sources of n-3 LCPUFAs, although DPA is generally a 
minor  quantitative  component  compared  to  EPA  and  DHA.  Food  supplements  containing  mainly 
EPA, or mainly DHA (isolated from microalgae), are also available. Pure DPA is not commercialised 
for human consumption. 
The n-3 LCPUFAs are present in foods and food supplements mainly as triacylglycerols (TAGs), and 
as free fatty acids or bound to phospholipids in smaller amounts. EPA and DHA may be found in the 
form of ethyl esters in synthetically produced concentrated supplements. In krill, EPA and DHA are 
mainly bound to phospholipids.   
Lipid peroxidation may occur during the processing and storage of foods and food supplements rich in 
n-3 LCPUFA in the absence of appropriate amounts of antioxidants (e.g. vitamin E).  
2.2.  Dietary intakes 
Mean  intakes  of  n-3  LCPUFA  in  European  countries  vary  according  to  sex,  age  group,  and 
supplementation habits (Appendices A, B and C). There is a large diversity in the methodology used 
to  assess  the  individual  intakes  of  children,  adolescents  and  adults.  These  differences  in  dietary 
assessment methods make direct comparisons difficult. Age classifications may not be uniform and 
comparability is also hindered by differences in food composition tables used for the conversion of 
food consumption data to nutrient intake data (Deharveng et al., 1999). Although these differences 
have an impact on the accuracy of between-country comparisons, the data presented give a rough 
overview of average intakes and intakes in high consumers of n-3 LCPUFA in a number of European 
countries.  
References were selected in order to obtain data on intake distributions and/or high consumption of 
n-3 LCPUFA individually or collectively in national surveys, in large cohorts and/or in populations of 
fish consumers.   
2.2.1.  Adults 
2.2.1.1.  EPA 
Mean daily intakes of EPA from food only were between 50 mg/day (Spain, both sexes, occasional 
fish consumers, 35-65 years) and 150 mg/day (France, men,  45 years), and median daily intakes 
between 14 mg/day (Belgium, women, 18-39 years) and 180 mg/day (Denmark, men, 50-64 years). 
Data from surveys considering food and food supplements combined reported slightly higher mean 
daily intakes of EPA in the general adult population (up to 330 mg/day, Norway, 16-79 years). Daily 
intakes of EPA from food only in the highest percentiles of consumption (P95) from the few surveys 
which  reported  on  this  outcome  were  between  308  mg/day  (France,  women,  35  years)  and 
428 mg/day (Belgium, women, 18-39 years). The high percentiles available for Denmark (P75) were 
within  that  range.  In  high  seafood  consumers,  mean  daily  intakes  from  food  only  ranged  from 
320 mg/day  (Spain,  35-65  years)  to  991 mg/day  (France,  18 years,  fifth  quintile  of  EPA-DHA 
intake). No surveys reported on EPA intakes from food and supplements combined in high seafood 
consumers. Tolerable Upper Intake Level of EPA, DHA and DPA 
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2.2.1.2.  DHA 
Mean  daily  intakes  of  DHA  from  food  only  were  between  131  mg/day  (Belgium,  women, 
18-39 years)  and  273  mg/day  (France,  men,  45 years),  and  median  daily  intakes  between 
42.5 mg/day (Belgium, women, 18-39 years) and 430 mg/day (Denmark, men, 50-64 years). Data 
from surveys considering food and food supplements combined reported higher mean daily intakes of 
DHA in the general adult population (up to 490 mg/day, Norway, 16-79 years). Daily intakes of DHA 
in the highest percentiles of consumption (P95) for the few surveys reporting on this outcome were 
between 574 mg/day (France, women,  35 years) and 668 mg/day (France, men,  45 years) from food 
only. The high percentiles available for Denmark (P75) were within that range. Mean daily intakes in 
high seafood consumers from food only were between 600 mg/day (Finnish, women,  18 years) and 
1,709 mg/day (France,  18 years, fifth quintile of EPA-DHA intake). No surveys reported on DHA 
intakes from food and supplements combined in high seafood consumers. 
2.2.1.3.  DPA 
Mean daily intakes of DPA from food only were between 25 mg/day (Belgium, women, 18-39 years) 
and 75 mg/day (France, men,  45 years), and median daily intakes between 12 mg/day (Belgium, 
women, 18-39 years) and 80 mg/day (Denmark, men, 50-64 years). Daily intakes of DPA from food 
only in the highest percentiles of consumption (P95) from the few surveys which reported on this 
outcome were between 100 mg/day (Belgium, women, 18-39 years) and 138 mg/day (France, men, 
45 years). The high percentiles available for Denmark (P75) were within that range. Data from food 
and  food  supplements  combined  were  within  these  ranges.  Mean  daily  intakes  in  high  seafood 
consumers from food only were up to 129 mg/day (France, men, 18-64 years).  
2.2.1.4.  EPA and DHA/total n-3 LCPUFA 
Mean daily intakes of EPA and DHA from food only were between 127 mg/day (Germany, women, 
18-24 years) and 295 mg/day (Germany, men, 45-54 years). Daily intakes of EPA and DHA in the 
highest  percentiles  of  consumption  (P95)  were  between  285 mg/day  (The  Netherlands,  women, 
19-30 years) and 1,115 mg/day (Belgium, women, 18-39 years), going up to 1,278 mg/day (Ireland, 
51-64 years) when food and food supplements were considered together. Mean intakes of EPA and 
DHA  in  high  fish  consumers  from  food  only  were  up  to  2,700 mg/day  (France,  18 years, fifth 
quintile  of  EPA-DHA  intake).  No  surveys  reported  on  EPA  and  DHA  intakes  from  food  and 
supplements combined in high seafood consumers. 
Mean daily intakes of EPA, DHA and DPA were about 400-500 mg/day (France, women  35 years 
and males  45 years), increasing to 2,570 mg/day (Norway, males, 16-79 years, fourth quartile of 
n-3 LCPUFA) when food and food supplements were considered together. Data from another survey 
considering food and fish oil combined for total n-3 LCPUFA were within these ranges. 
2.2.2.  Children 
No population-based data were available for infants.  
2.2.2.1.  Young children (1-3 years) 
Intake data were available for Germany (EPA and DHA from food only excluding fortified food) and 
Norway (EPA, DHA and DPA considering also food supplements).  
Mean daily intakes of EPA and DHA in German girls and boys, aged 2 to   4 years consuming fish 
were 100 to 118 mg/day. Mean intakes of EPA, DHA and DPA in Norwegian children aged 1 or 
2 years were 400-600 mg/day (95
th percentiles 1,400-1,700 mg/day).  Tolerable Upper Intake Level of EPA, DHA and DPA 
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2.2.2.2.  Children aged 3-13 years 
Data from food and food supplements combined were available for this age group for individual fatty 
acids  (Sweden),  for  EPA  and  DHA  combined  (The  Netherlands),  and  for  EPA,  DHA  and  DPA 
combined (Norway). Mean daily intakes in German fish consumers in a survey which considered 
intake of EPA and DHA from food only and excluding fortified foods have been reported to be lower 
than the high consumers (95
th percentile) in surveys considering food and food supplements. 
Mean daily intakes of EPA in Swedish children (4-12 years) were 40 mg/day, and the 95
th percentiles 
of intake varied between 140 mg/day (4 years) and 170 mg/day (8-9 years).  
Mean daily intakes of DHA in this population subgroup were between  100 mg/day (4 years) and 
120 mg/day  (8-12  years).  The  95
th  percentiles  of  intake  were  between  320 mg/day (4 years) and 
420 mg/day (8-12 years).  
Mean daily intakes of DPA were between 30 mg/day (4 years) and 40 mg/day (8-12 years), and the 
95
th percentiles of intake varied from 70 mg/day (4 years) to 90 mg/day (8-12 years).  
In Dutch children (7-13 years), median daily intakes of EPA and DHA were between 62 mg/day (boys 
7-8 years)  and  66  mg/day  (girls  7-13  years).  Higher  percentiles  of  intake  (P95)  were  between 
264 mg/day (girls, 9-13 years) and 317 mg/day (boys, 9-13 years). Mean daily intakes of EPA, DHA 
and DPA in Norwegian children aged 4-9 years were 300-400 mg/day, and the 95
th percentiles were 
1,200-1,400 mg/day. 
2.2.2.3.  Adolescents (13-19 years) 
Data for the individual fatty acids EPA, DPA and DHA from food only were available from Belgium 
in children of both sexes aged 13-18 years. For DHA, mean daily intakes were 111 mg/day, and the 
95
th percentile was 363 mg/day. Mean daily intakes for EPA was 56 mg/day, and the 95
th percentile 
was 244 mg/day. Mean daily intakes for DPA were 18 mg/day, and the 95
th percentile was 63 mg/day.  
The highest mean daily intakes of EPA and DHA combined from food (excluding fortified food) were 
reported in German fish consumers aged 13-14 years (girls, 214 mg/day) and 15-18 years (boys, 
324 mg/day)  which  increased  up  to  536  mg/day  and  838  mg/day,  respectively,  on  days  of  fish 
consumption. Data in Dutch children from food and supplements combined were lower.  
In Norwegian adolescents aged 13 years, mean intakes for EPA, DHA and DPA combined from food 
only  were  200 mg/day  (95
th  percentiles  of  700  mg/day),  and  300  mg/day  (95
th  percentile  was 
1,100 mg/day) when food and food supplements were considered. 
2.2.3.  Summary of intake data 
The Panel notes that mean daily intakes of n-3 LCPUFA in adults at the highest percentiles of intake 
were generally <1,200 mg/day from food only, and <1,300 mg/day when food supplements were 
considered  as  well.  In  high  fish  consumers  daily  intakes  of  n-3  LCPUFA  from  food  only  were 
<2.7g/day. No surveys reported on EPA and DHA intakes from food and supplements combined in 
high seafood consumers. 
In children, the highest intakes of n-3 LCPUFA were observed in children aged 1-2 years consuming 
food supplements (95
th percentiles 1,400-1,700 mg/day).   Tolerable Upper Intake Level of EPA, DHA and DPA 
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2.3.  Digestion and absorption 
Triacylglycerols  represent  the  major  dietary  form  of  n-3  LCPUFA,  where  three  fatty  acids  are 
esterified to a glycerol backbone and represent more than 90 % by weight. Owing to the asymmetric 
structure of substituted glycerol, the esterified fatty acids are distinguished by their position, namely 
the sn-1, sn-2 and sn-3 position. Considering their metabolic fate (action of lipases) in the digestive 
tract, sn-1 and sn-3-esterified fatty acids are considered as esterified at “external” positions, whereas 
the sn-2 position is considered as “internal”.  
TAGs undergo lipolysis by lipases in the gastrointestinal tract prior to absorption. Although there are 
lipases in the saliva and gastric secretion, most lipolysis occurs in the small intestine (IoM, 2005). In 
the intestine, TAGs are emulsified with bile salts and phospholipids secreted into the intestine in bile, 
hydrolysed by pancreatic enzymes, and almost completely absorbed.  Pancreatic lipase has a high 
specificity for the sn-1 and sn-3 position of dietary triacylglycerols so that free fatty acids from the 
sn-1 and sn-3 position and 2-monoacylglycerol are released for absorption. The pancreatic lipase also 
completely hydrolyses  ethyl esters into fatty acids and the ethanol backbone, although the affinity of 
the lipase for the fatty acid-ethanol bond appears to be lower than for the fatty acid-glycerol bond. 
Dietary phospholipids are hydrolysed by pancreatic phospholipase A2 prior to absorption.  
Dietary EPA and DHA are absorbed into the enterocyte as free fatty acids or 2-monoacylglycerol, 
where they are incorporated into TAGs. The TAGs are then assembled together with cholesterol, 
phospholipids, and apoproteins into chylomicrons, which enter the circulation. Data are scarce for 
DPA, but there is no reason to assume that digestion and absorption of DPA might be different from 
EPA and DHA. 
Both  comparable  and  lower  rates  of  absorption  and  incorporation  of  EPA  and  DHA  into  cell 
membranes and tissues have been reported for ethyl esters compared to TAGs. Conversely, higher 
rates of absorption and incorporation of EPA and DHA into cell membranes and tissues have been 
reported for phospholipids compared to TAGs. However, as the safety assessment of EPA, DHA and 
DPA refers to long-term consumption and these fatty acids are absorbed almost completely regardless 
of the source, the Panel considers that there is no need to undertake separate safety assessments for 
different sources of n-3 LCPUFA. This Opinion refers to EPA, DHA and DPA from all sources.  
2.4.  Metabolism 
Circulating n-3 LCPUFAs are either used as a source of energy (i.e. oxidised to carbon dioxide and 
water), incorporated into tissue lipids, or utilised in eicosanoid synthesis. Small amounts are lost 
during sloughing of skin and other epithelial cells (IoM, 2005). 
ALA is essential in human nutrition as a precursor for n-3 LCPUFA. EPA, DPA and to a lesser degree 
DHA are synthesised from ALA through the sequential action of various desaturases and elongases in 
animal tissues, but not in plants. Estimates for the conversion of ALA into EPA, DPA and DHA are 
low, and even lower when dietary intakes of these n-3 LCPUFAs are high (EFSA Panel on Dietetic 
Products Nutrition and Allergies (NDA), 2010). The Panel notes that endogenous production of EPA, 
DPA and DHA from ALA may be negligible compared to the doses used in the studies considered for 
the assessment of the safety of these n-3 LCPUFAs.   
DHA is a component of membrane structural lipids, especially of phospholipids in nervous tissue and 
the retina. EPA can be transformed to eicosanoids, a group of biologically active substances including 
prostaglandins, prostacyclins and leukotrienes which participate in the regulation of blood pressure, 
renal function, blood coagulation, inflammatory and immunological reactions and other functions in 
tissues; EPA is also the precursor for series 3 prostanoids and series 5 leukotrienes (Kinsella et al., 
1990). Other metabolites of EPA and DHA (resolvins, protectins) are thought to be involved in the 
resolution of the inflammatory response. Both EPA and DHA are incorporated into cell membranes, 
and thus may impact cellular metabolism, signal transduction, and regulation of gene expression. Tolerable Upper Intake Level of EPA, DHA and DPA 
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Although DPA can be retro-converted to EPA and only minimally to DHA, little is known about the 
biological effects of DPA in vivo (Kaur et al., 2011). As acyl chain length and degree of saturation 
may affect the function of fatty acids in biological membranes, it is expected that alterations in the 
content  of  these  fatty  acids  will  differentially  affect  membrane  structure  and  function.  Indeed, 
different effects of EPA, DHA and DPA on enzyme activity, gene expression and platelet aggregation 
have been described in vitro (Kaur et al., 2011; VKM, 2011). However, the exact molecular and 
cellular effects of each of the n-3 LCPUFA, and their impact on disease outcomes in vivo, are not 
precisely known. 
High dietary intakes of EPA and DHA result in decreased tissue concentrations of arachidonic acid 
(AA) and increased concentrations of EPA and DHA, respectively. Supplementation with DHA is 
also accompanied by an increase in EPA, which could be explained by retroconversion of DHA to 
EPA or by inhibition of further metabolism of the EPA formed from ALA. These effects of DHA 
supplementation induce changes in AA metabolism and in the balance of eicosanoids synthesized 
from the n-6 and n-3 fatty acids, and thus may have an impact on the functions partially regulated by 
eicosanoids cited above (IoM, 2005).  
The  Panel  notes  that  although  endogenous  inter-conversion  of  EPA,  DPA  and  DHA  may  occur 
in vivo, and particularly when either fatty acid (mainly EPA and DHA) is administered in isolation at 
high  doses,  this  inter-conversion  is  considered  to  be  negligible  when  they  are  administered  in 
combination at the dose levels used in the studies considered for the assessment of their safety. The 
Panel also notes that different biological effects of EPA, DPA and DHA cannot be excluded, and that 
the effects of these n-3 LCPUFAs may depend on the mode of administration (e.g., given alone vs. 
given in combination).  
2.5.  Requirements and dietary reference values 
ALA is an essential fatty acid required to maintain metabolic integrity and is a precursor of EPA, 
DPA and to a lesser degree DHA. Whereas some authoritative bodies and organisations have set 
dietary recommendations for total n-3 PUFAs (primarily ALA, EPA, DHA and DPA in combination) 
for different population subgroups, or for ALA as the essential precursor of EPA, DPA and DHA 
(IoM, 2005), many authorities have separate recommendations for ALA on the one hand, and for the 
n-3 LCPUFAs (either as total n-3 LCPUFAs or as EPA and DHA) on the other hand, owing to the 
different biological functions attributed to ALA and to the n-3 LCPUFAs (EFSA Panel on Dietetic 
Products Nutrition and Allergies (NDA), 2009, 2010). 
Dietary recommendations from national and international bodies for n-3 LCPUFAs (mostly as EPA 
and DHA) range from 200 mg to >600 mg/day for adults (Table 1), and from 40 mg to 250 mg/day for 
infants older than six months and for children and adolescents (Table 2). These recommendations 
have been generally based on the inverse relationship observed between the consumption of these n-3 
LCPUFAs (primarily from fish and fish oils) and a lower risk of coronary artery disease.  
Specific  recommendations  have  also  been  made  for  DHA  for  infants  and  young  children  (6  to 
24 months of age) ranging from 70-100 mg/day based on its accumulation in the central nervous 
system and its effects on visual function during the complementary feeding period (Table 2) and for 
additional DHA (100-200 mg/day) for pregnant and lactating women  to compensate for oxidative 
losses of maternal dietary DHA and accumulation of DHA in body fat of the fetus/infant (Table 1).  
The Panel notes that the highest dietary recommendations for EPA and DHA (mostly as EPA and 
DHA or as DHA alone) for different population subgroups are 610 mg/day (Australia). The Panel also 
notes  that  the  highest  recommendations  for  EPA  and  DHA  combined  for  European  adults  and 
children  (250-500  mg/day)  are  based  on  the  reduction  of  CVD  risk,  and  that  no  dietary 
recommendations have been made specifically for DPA. Tolerable Upper Intake Level of EPA, DHA and DPA 
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Table 1:   Recommended  dietary  intakes  for  n-3  polyunsaturated  fatty  acids  from  national  and 
international bodies (adults)
1. 
National/International Body 
n-3 PUFA  ALA  EPA+DHA
2 
% of 
energy  g/day  % of 
energy  g/day  % of 
energy  mg/day 
(WHO/FAO, 2003)  1-2  -  -  -  -  200-1000/wk 
United Kingdom, 
(DoH, 1991, 1994) 
-  -  >0.2  -  -  200 
(SACN, 2004)  -  -  -  -  -  450 
(Eurodiet, 2000)  -  -  -  2  -  200 
Belgium, Superior Health Council 
(CSS, 2009; SHC, 2004) 
1.3-2.0  -  >1  -  0.3   
Australia, (Ministry of Health-
Department of Health and Ageing - 
National Health and Medical 
Research Council, 2006) 
           
     Adult men  -  -  -  1.3  -  610
3 
     Adult women  -  -  -  0.8  -  430
3 
     Pregnancy  -  -  -  1.0  -  115
4 
     Lactation  -  -  -  1.2  -  145
4 
The Netherlands,  
(Health Council, 2001, 2006) 
-  -  1  -  -  450 
Nordic Countries, (NNR, 2004)  1  -  -  -  -  - 
France, (ANSES, 2010)      1      500 (250 DHA) 
USA, (IoM, 2005)             
     Adult men  -  -  -  1.6  -  - 
     Adult women  -  -  -  1.1  -  - 
     Pregnancy  -  -  -  1.4  -  - 
     Lactation  -  -  -  1.3  -  - 
Germany, Austria, Switzerland,  
(D-A-CH, 2012) 
-  -  0.5  -  -  - 
     Pregnancy  -  -  -  -  -  200 (DHA) 
     Lactation  -  -  -  -  -  200 (DHA) 
(EFSA Panel on Dietetic Products 
Nutrition and Allergies (NDA), 
2010) 
    0.5      250 
    Pregnancy and lactation            +100-200 (DHA) 
1 Values for pregnancy and lactation are only indicated if different from those for adult women. 
2Values in bold refer to n-3 
LCPUFA (EPA, DHA and DPA); 
3Suggested Dietary Target; 
4 Adequate Intakes. Tolerable Upper Intake Level of EPA, DHA and DPA 
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Table 2:    Recommended  dietary  intakes  for  n-3  polyunsaturated  fatty  acids  from  national  and 
international bodies (children). 
National/International Body 
n-3 PUFA  ALA  EPA+DHA
1 
% of 
energy  g/day  % of 
energy  g/day  % of energy  mg/day 
United Kingdom,  
(DoH, 1991, 1994) 
-  -  0.2    -  - 
      5 years  -  -  -  -  -  200 
Belgium, Superior Health 
Council, (CSS, 2009) 
           
      0-12 mo  -  -  -  0.5  -  - 
         >1 y  -  -  0.45-1.50  -  0.1-0.4 DHA 
0.05-0.15 EPA 
- 
Australia, (Ministry of Health-
Department of Health and Ageing 
- National Health and Medical 
Research Council, 2006) 
           
      0-1 y  -  0.5  -  -  -  - 
      1-3 y  -  -  -  0.5  -  40 
      4-8 y  -  -  -  0.8  -  55 
    9-13 y boys  -  -  -  1.0  -  70 
               girls  -  -  -  0.8  -  70 
  14-18 y boys  -  -  -  1.2  -  125 
               girls  -  -  -  0.8  -  85 
The Netherlands, (Health 
Council, 2001) 
           
 
   0-5 mo  -  -  -  0.08/kg  -  20/kg (DHA) 
   6 mo-18 y  -  -  1  -  -  150-200 
Nordic Countries, (NNR, 2004)  1  -  -  -  -  - 
France, (ANSES, 2010)             
     0-6 mo  -  -  0.45  -  -  DHA: 0.32 % 
of total FAs, 
EPA<DHA 
     6 mo-3y  -  -  0.45  -  -  70 (DHA) 
     3-9 y  -  -  1  -  -  250 (125 DHA) 
  10-18 y  -  -  1  -  -  500 (250 DHA) 
USA, (IoM, 2005)             
      0-6 mo  -  0.5         
      7-12 mo  -  0.5         
      1-3 y  -  -  -  0.7  -  - 
      4-8 y  -  -  -  0.9  -  - 
    9-13 y boys  -  -  -  1.2  -  - 
               girls  -  -  -  1.0  -  - 
  14-18 y boys  -  -  -  1.6  -  - 
               girls  -  -  -  1.1  -  - 
Germany, Austria, Switzerland, 
(D-A-CH, 2012) 
-  -  0.5  -  -  - 
(EFSA Panel on Dietetic 
Products Nutrition and Allergies 
(NDA), 2010) 
           
      7-24 mo  -  -  0.5  -  -  100 (DHA) 
      2-18 y  -  -  0.5  -  -  250 
1Values in bold refer to n-3 LCPUFA (EPA, DHA and DPA). Tolerable Upper Intake Level of EPA, DHA and DPA 
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3.  Hazard identification 
Adverse  effects  which  have  been  described  in  humans  in  association  with  high  intakes  of  n-3 
LCPUFA include bleeding episodes, impaired immune function, increased lipid peroxidation, and 
impaired lipid and glucose metabolism.  
The majority of human intervention studies which have investigated the effects of n-3 LCPUFA on 
different  health  outcomes  have  used  fish  oils  containing  known  amounts  of  EPA  and  DHA  and 
generally unknown (but relatively low) amounts of DPA; EPA and DHA in combination as ethyl 
esters; or more rarely EPA alone or DHA alone. Very few studies are available using krill oil as a 
source of EPA and DHA, and no studies have been conducted with sources containing mainly DPA or 
with DPA alone.  
Long-term human intervention studies which have investigated the effects of supplemental intakes of 
EPA and DHA, either alone or in combination, at doses up to about 1 g/day on a variety of health 
outcomes (e.g. cardiovascular, neurological and immunological) have generally reported no adverse 
effects in relation to the consumption of EPA or DHA at these dose levels. 
3.1.  Bleeding complications, bleeding time and platelet function 
3.1.1.  Bleeding complications 
An increased tendency to bleed from the nose and urinary tract, and an increased mortality from 
haemorrhagic stroke, have been reported in Greenlandic Inuits with high intakes of fatty fish (mean 
intakes of n-3 LCPUFA about 6.5 g/day), as well as increased bleeding times and reduced platelet 
aggregation in vitro (IoM, 2005). The Panel notes that these studies were uncontrolled for factors 
other than dietary n-3 LCPUFA which may have been responsible for the effects.  
The hypothesis that n-3 LCPUFA supplementation could modify platelet function, increase bleeding 
time and, eventually, increase the risk of spontaneous bleeding and haemorrhagic stroke, has been 
addressed in several controlled human intervention studies.  
Data on the effects of n-3 LCPUFA on the risk of haemorrhagic stroke are scarce. One open label 
human intervention study (Yokoyama et al., 2007) which investigated the effects of 1.8 g/day of EPA 
as  ethyl  esters  consumed  for  five  years  in  combination  with  statins  (n=9,326)  vs.  statins  alone 
(n=9,319) in hypercholesterolemic, high fish consumers on the primary and secondary prevention of 
coronary heart disease also assessed safety outcomes and the risk of stroke and its subclasses (Tanaka 
et  al.,  2008).  Bleeding  (cerebral  and  fundal  bleedings,  epistaxis,  and  subcutaneous  bleeding 
combined) was more frequently reported in the EPA group than in controls. The Panel notes that nose 
or subcutaneous bleeding for example was self-reported, and that self-reported side effects are subject 
to high reporting bias in open label studies. The Panel also notes that no significant differences in the 
total incidence of stroke, or in the incidence of cerebral or subarachnoid haemorrhage, which were 
objectively assessed, were observed between groups. The Panel considers that intakes of EPA alone at 
doses up to 1.8 g/day for two years do not increase the risk of bleeding complications. 
Among the several prospective cohort studies published to date on the relationship between dietary 
intake of n-3 LCPUFA and risk of stroke, none has reported an increased risk of haemorrhagic stroke 
(He et al., 2002; IoM, 2005; Skerrett and Hennekens, 2003). Mean dietary intakes of n-3 LCPUFA at 
the highest quintiles of intake in these studies were <1 g/day.  
The Panel notes that there is no evidence for an increased risk of haemorrhagic stroke at doses of n-3 
LCPUFA which are usually consumed in Western diets, or at supplemental intakes of mostly EPA up 
to 1.8 g/day.   Tolerable Upper Intake Level of EPA, DHA and DPA 
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Some controlled human intervention studies on the effects of n-3 LCPUFA on bleeding complications 
other than haemorrhagic stroke have been conducted in population subgroups at high risk of bleeding, 
and which include patients on antiplatelet or antithrombotic medications (acetyl salicylic acid ASA, 
clopidogrel, anticoagulants) undergoing invasive procedures, and pregnant women at delivery.  
A Cochrane review (Hooper et al., 2004) including 48 radomised controlled trials (RCTs) conducted 
in subjects at high risk of cardiovascular events addressed the effects of n-3 LCPUFA at doses of 0.4 
to  7 g/day  (compared  to  placebo  or  to  a  control  oil)  for  at  least  six  (and  up  to  47)  months  on 
CVD-related  outcomes.  The  majority  of  subjects  were  under  antithrombotic  medications  for  the 
prevention or treatment of CVD. Seven of the studies, which used EPA and DHA at doses of 1.8 to 
6.9 g/day for 6 to 24 months, reported on bleeding episodes (Bairati et al., 1992; Eritsland et al., 1996; 
Franzen et al., 1993; Kaul et al., 1992; Leaf et al., 1994; Loeschke et al., 1996; Reis et al., 1991). No 
difference  in  the  risk  of  bleeding  between  the  intervention  (n=17/949)  and  control  (or  placebo, 
n=13/836) groups was observed. The study which used the highest dose of n-3 LCPUFA (6.9 g/day) 
lasted six months (Leaf et al., 1994) and the study of longest duration (24 months) used 5.1 g/day of 
EPA and DHA (Loeschke et al., 1996). 
Harris (2007) reviewed 19 controlled intervention studies (4,397 subjects) in patients on secondary 
prevention for coronary heart disease (CHD) undergoing major vascular surgery or femoral puncture 
for diagnostic purposes who received EPA and DHA (1.4 to 6.9 g/day) from different sources (fish oil 
or capsules with EPA and DHA as triglycerides or ethyl esters) for 1-28 months. This review included 
six of the seven studies (all except Loeschke et al., 1996) considered by Hooper et al. (2004). Except 
in two studies (Nye et al., 1990; Rapp et al., 1991), subjects were on antithrombotic medications 
(ASA, warfarin or heparin). Even if these studies were not specifically designed to address the safety 
of n-3 LCPUFA, they all reported on adverse events in general and on bleeding complications in 
particular. None of the studies observed an increased frequency or severity of bleeding complications 
associated  with  EPA  and  DHA  supplementation.  Besides  Leaf  et  al.  (1994),  the  study  using  the 
highest dose of n-3 LCPUFA (6 g/day) lasted 4.5 months (Cairns et al., 1996) and the study of longest 
duration (28 months) used 4.8 g/day of EPA and DHA (Sacks et al., 1995).   
Also a recent meta-analysis of RCTs (Filion et al., 2010) on the effects of n-3 LCPUFA (EPA and 
DHA  given  at  doses  of  0.9-6.9  g/day  for  1-55  months)  on  mortality  (25  RCTs,  mean  duration 
12 months)  and  re-stenosis  following  angioplasty  (14  RCTs,  mean  duration  six  months)  in 
populations with (or at high risk of) CHD addressed safety outcomes, including bleeding. The risk of 
bleeding was not significantly different between the intervention and control groups in the 15 RCTs 
which reported on this outcome and entered data analysis. Of these, only four studies had not been 
considered by Harris (2007), three of which used either low doses (1 g/day) of n-3 LCPUFA (Rauch 
et al., 2010), had a very short duration (days) of the intervention (Calo et al., 2005) or included a 
small sample of patients (Rossing et al., 1996).  
Supplementation studies (n=31) with n-3 LCPUFA in patients (n=485) with end-stage renal disease 
undergoing dialysis and treated with antithrombotic medications (mostly ASA) which reported on 
bleeding  complications  were  reviewed  by  Friedman  and  Moe  (2006).  Most  studies  were  small 
(<20 subjects),  uncontrolled  or  not  randomised  (n=21), lasted 4 to 24 weeks, and all  except two 
(which provided EPA alone at doses of 1.8 and 3 g/day, respectively) used fish oil at doses of 1.4 to 
7.6 g/day. The RCTs had generally bigger sample sizes, were of longer duration ( 8 weeks) and used 
EPA  or  fish  oil  at  doses  of  1.8  to  5.2 g/day.  Only  one  case  of  serious  gastrointestinal  bleeding 
required  hospitalisation  and  was  reported  in  one  small  uncontrolled  study  (n=7)  in  a  patient 
consuming 3 g/day of EPA, but the event could not be attributed to the EPA treatment (Diskin et al., 
1990). There were no studies which reported on bleeding episodes using DHA in isolation at these 
dose levels. One single-arm intervention study was also available in children with end-stage renal 
disease on dialysis and at high risk of bleeding  (Goren et al., 1991). A total of 16 children and 
adolescents (7 to 18 years) with hyperlipidaemia were given 3 to 8 g/day (weight-adjusted dose) of 
fish oil (0.3 to 2.4 g/day of EPA and DHA) for eight weeks, and were followed up for one month after Tolerable Upper Intake Level of EPA, DHA and DPA 
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treatment. Platelet counts were normal in all subjects and mild side effects of treatment (abdominal 
cramps and diarrhoea which resolved spontaneously) did not include spontaneous bleeding.  
In a single-arm intervention (Sorgi et al., 2007), nine children and adolescents (8–16 years) under 
treatment for attention-deficit hyperactivity disorder (ADHD) received 30 mL of a liquid EPA/DHA 
which provided 16.2 g of n-3 LCPUFA (10.8 g EPA and 5.4 g DHA) per day for 4 weeks. Then doses 
were adjusted to maintain the AA:EPA ratio in the isolated plasma phospholipids between 1.5 and 3, 
so that three, two and four subjects consumed 8.1, 10.8 and 16.8 g/day, respectively, for another four 
weeks. No bleeding episodes were reported for any of the children during the eight-week study.  
No increased risk of bleeding complications at delivery was observed in pregnant women (n=533) 
who received 2.7 g/day n-3 LCPUFA from fish oil during the last trimester compared to olive oil or 
no supplement (Olsen et al., 1992).   
The  Panel  notes  that  some authoritative bodies have warned about an increased risk of bleeding 
complications at supplemental doses of these n-3 LCPUFAs of  3 g/day. The concern was raised by 
one human intervention study in children which reported nose bleeding episodes associated with the 
consumption of fish oil (Clarke et al., 1990).  
The study by Clarke et al. (1990) was a single-arm intervention on the effects of fish oil on blood 
lipids  conducted  in  11  children  and  adolescents  with  familial  hyperlipoproteinaemia  (aged  11  to 
21 years) who received an increasing dose of fish oil (18 % EPA and 12 % other n-3 fatty acids) for 
six months (starting at 1 g/day the first month and increasing by 1 g/day monthly up to 5 g/day) after 
three months of pre-treatment observation. Subjects were followed  after treatment for one month. 
Doses of EPA and DHA ranged from 0.3 to 1.5 g/day during the study. Eight of the 11 subjects 
reported  nine episodes of epistaxis (nose bleeding) during the fish oil supplementation and none 
during the pre- and post-observation periods. In one case the intervention was stopped due to epistaxis 
with prolongation of bleeding time when doses of 1.5 g/day of EPA and DHA were being consumed. 
In two subjects, epistaxis was associated with modest prolongation of bleeding time (one subject was 
on  ASA),  whereas  one  subject  who  withdrew  due  to  epistaxis  had  a  normal bleeding time. One 
subject  had  asymptomatic  occult  blood  in  the  stool  on  one  occasion  with  normal  bleeding  time. 
Platelet  counts,  prothrombin  and  partial  thromboplastin  times  were  within  the  normal  range.  No 
information was provided in the publication about the time at which eight of the nine episodes of 
epistaxis occurred, nor about the dose of EPA and DHA being consumed at the time of the events. 
The Panel notes the uncontrolled nature and poor reporting of the study (e.g. medication use).  
The Panel notes that the bleeding episodes associated with the consumption of fish oil reported by 
Clarke et al. (1990) have not been observed in other studies of similar design conducted with higher 
doses of EPA and DHA in children at low (Sorgi et al., 2007) or high (Goren et al., 1991) risk of 
bleeding, or in a number of controlled intervention studies in adults at high risk of bleeding. 
The Panel considers that supplemental intakes of EPA and DHA combined of up to about 5 g/day for 
up to two years and up to about 7 g/day for up to six months, do not increase the risk of spontaneous 
bleeding episodes or bleeding complications, even in subjects at high risk of bleeding (e.g. taking 
acetylsalicylic acid or anti-coagulants). The Panel notes that the data available are insufficient to 
conclude on whether the same doses administered mostly as EPA or mostly as DHA would have 
different  effects  on  this  outcome.  The  Panel  considers  that intakes of EPA alone at doses up to 
1.8 g/day for two years do not increase the risk of bleeding complications.  
3.1.2.  Bleeding time 
An increase in bleeding time beyond the normal range and/or leading to bleeding complications is 
considered an adverse effect. However, changes in bleeding time which are within the normal range Tolerable Upper Intake Level of EPA, DHA and DPA 
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and  which  are  not  associated  with  bleeding  complications  may  not  be  considered  adverse.  The 
predictive  value  of  changes  in  bleeding  time  within  the  normal  range  in  relation  to  bleeding 
complications is low.   
A number of small, short-term (4-11 weeks) controlled intervention studies have examined the effects 
of n-3 LCPUFA at doses of 2-15 g/day (most between 3 and 6 g/day) on bleeding time in healthy 
subjects  and  in  subjects  with  hypercholesterolemia,  hypertension,  type  2  diabetes,  patients  with 
atherosclerosis undergoing coronary artery bypass graft surgery, or a combination of these, who were 
not under medications prolonging bleeding time, such as ASA or anti-coagulants (IoM, 2005). The 
majority  of  these  studies  reported  a  significant  increase  in  bleeding  time  with  n-3  LCPUFA 
supplementation (Cairns et al., 1996; Cobiac et al., 1991; DeCaterina et al., 1990; Emsley et al., 2008; 
Levinson et al., 1990; Lorenz et al., 1983; Mortensen et al., 1983; Sanders et al., 1981; Schmidt et al., 
1990; Smith et al., 1989; Thorngren and Gustafson, 1981; Wojenski et al., 1991; Zucker et al., 1988) 
whereas other studies using doses up to 6 g/day resulted in no difference (Blonk et al., 1990; Freese 
and Mutanen, 1997; Nelson et al., 1997; Rogers et al., 1987). All changes in bleeding times were 
within the normal range and did not lead to spontaneous bleeding. The Panel also notes that only a 
few studies have addressed the effects of supplements containing mostly EPA (Emsley et al., 2008; 
Wojenski et al., 1991) or mostly DHA (Nelson et al., 1997).  
Three of the studies specifically assessed dose-response relationships between n-3 LCPUFA intakes 
and  bleeding  time.  Blonk  et  al.  (1990)  supplemented  45  healthy  normotriglyceridaemic  male 
volunteers with 1.5, 3 or 6 g/day of EPA and DHA as ethyl esters for 12 weeks. No significant effect 
on  bleeding  time  was  observed  for  any  of  the  doses  tested.  Schmidt  al.  (1990)  supplemented 
ten healthy males with increasing doses of n-3 LCPUFA (1.3 g, 4 g or 9 g/day) from fish oil daily for 
periods of six weeks each. Bleeding time increased significantly compared to baseline after the 4 g 
and the 9 g doses in a dose-dependent manner. A more recent intervention study (Cohen et al., 2011) 
examined the effects of increasing doses of EPA and DHA as ethyl esters (1, 2, 4 and 8 g/day for six 
consecutive weeks each, 24 weeks in total), either alone, in combination with ASA, or in combination 
with  ASA  plus  clopidogrel,  in  30 volunteers  (ten  subjects  per  group).  Median  bleeding  times 
increased within the normal range in a dose-dependent manner with increasing doses of EPA and 
DHA given alone. No effect was reported in the ASA or the ASA plus clopidogrel groups which 
already had prolonged bleeding times.  
Four controlled studies (reviewed in VKM, 2011) assessed bleeding time in subjects supplemented 
with n-3 LCPUFA who were under ASA, and/or the international normalised ratio (INR) in subjects 
on warfarin as antithrombotic therapy at doses from 0.9 to 6.9 g/day (Bender et al., 1998; Dehmer et 
al., 1988; Eritsland et al., 1996; Leaf et al., 1994). Three studies observed no significant differences in 
bleeding times between the intervention group and controls, whereas the fourth study (Leaf et al., 
1994) did not compare the study groups directly. The Panel notes that n-3 LCPUFA supplementation 
did not lead to spontaneous bleeding or bleeding complications in any of the studies.   
The Panel notes that supplemental intakes of EPA and DHA combined of up to about 6 g/day do not 
enhance  the  effects  of  anti-platelet  or  antithrombotic  medications  on  bleeding  time,  and  that  the 
changes in bleeding times within the normal range which have been observed in some intervention 
studies are not considered to be adverse as they were not associated with an increased risk of clinical 
complications (e.g. spontaneous bleeding). 
3.1.3.  Platelet function 
Platelet  dysfunction  leading  to  bleeding  complications  is  considered  an  adverse  effect.  However, 
changes  in  platelet  function  which  are  not  associated  with  bleeding  complications  may  not  be 
considered adverse.  Tolerable Upper Intake Level of EPA, DHA and DPA 
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Several,  mostly  short-term,  intervention  studies  have  investigated  the  effects  of  n-3  LCPUFA  on 
platelet function assessed by different methods and using a variety of outcome measures. 
Violi  et  al.,  (2010)  recently  reviewed  published  studies  on  the  effects  of  EPA  and  DHA 
supplementation on platelet function. Among the 21 studies identified, only seven were controlled. Of 
these,  three  were  conducted  in  healthy  subjects  and  four  in  subjects  with  hypercholesteroaemia, 
hypertension,  type  2  diabetes,  or  a  combination  of  these.  Doses  of  n-3  LCPUFA  ranged  from 
1 to 4 g/day and study duration from 30 days to one year. No effect of n-3 LCPUFA intake on platelet 
aggregation was observed in the two studies of shorter and longer duration, respectively, whereas five 
studies observed inhibition of platelet function or prolongation of platelet survival (study duration 
4-16 weeks). The effect on platelet function did not appear to be dose-dependent. Dose-response 
relationships between the intake of EPA and DHA and platelet aggregation, vWF, coagulation factors 
VII and VIII, AT III activity, protein C activity, plasma fibrinogen, fibronectin and fibrinolysis (PAI 
and t-PA ag) were specifically assessed in one study on ten healthy males supplemented with 1.3 g, 
4 g or 9 g of n-3 LCPUFA daily for periods of six weeks each (Schmidt et al., 1990). No significant 
effect of EPA and DHA was observed on platelet aggregation.  Plasma fibrinogen decreased in a 
dose-dependent manner after intake of 1.3 g and 9 g of n-3 LCPUFA. The vWF decreased after the 
high  dose,  while  plasma  concentrations  of  factor  VII,  factor  VIII,  and  AT  III  activity,  protein C 
activity and fibronectin were unaltered by n-3 LCPUFA. At rest, PAI and t-PA ag. increased after 
intake of 9 g of n-3 LCPUFA, and PAI increased after n-3 LCPUFA ingestion in a dose-dependent 
fashion.  The  Panel  notes  that  no  effect  on  platelet  aggregation  was  observed  and  that  no 
dose-response  relationship  was  reported  between  the  intake  of  EPA  and  DHA  and  most  of  the 
variables related to blood coagulation.  
One of the studies specifically assessed whether DHA and EPA could have differential effects on 
platelet aggregation. In a double-blind placebo-controlled trial of parallel design, Woodman et al. 
(2003)  randomised  59  treated  hypertensive  Type  2  diabetic  men  and  postmenopausal  women  to 
4 g/day  of  EPA,  DHA  or  olive  oil  (placebo)  for  six  weeks.  DHA  but  not  EPA  supplementation 
significantly reduced collagen aggregation (by 16.9 %) and TXB2 (by 18.8 %), whereas no significant 
changes  were  reported  in  either  platelet  activating  factor  (PAF)-stimulated  platelet  aggregation, 
fibrinolytic  function  or  vascular  function  in  either  the  EPA  or  DHA  groups  relative  to  placebo. 
However, another study comparing 4 g/day of EPA to the same amounts of n-3 LCPUFA (mostly 
EPA and DHA) from a fish oil concentrate given for four weeks found EPA to being more effective in 
decreasing platelet aggregation than fish oil concentrate (Wojenski et al., 1991). The Panel notes that 
available  data  on  differential  effects  of  EPA  and  DHA  on  platelet  aggregation  are  scarce  and 
inconsistent. 
The Panel notes that the changes on platelet function which are observed at supplemental intakes of 
EPA and DHA (either alone or in combination) up to about 4 g/day are not considered to be adverse 
as they are not associated with an increased risk of clinical complications (e.g. spontaneous bleeding). 
3.2.  Glucose homeostasis 
Human  intervention  studies,  mostly  uncontrolled,  have  described  adverse  effects  of  supplemental 
n-3 LCPUFA ( 10 g/day) on glucose homeostasis, such as increased insulin requirements, an increase 
in glycated haemoglobin (HbA1c), and an increase in fasting and postprandial glycaemia, in patients 
with type 1 and type 2 diabetes (see De Caterina et al., 2007 for review). In 2005, the IoM advised 
that subjects with “impaired glucose tolerance or diabetic conditions requiring increased doses of 
hypoglycaemic agents” should take EPA and DHA supplements with caution (IoM, 2005).  
Data from (mostly controlled) human intervention studies with respect to the effects of n-3 LCPUFA 
supplementation on insulin requirements in type 1 diabetics, and on HbA1c and fasting/postprandial 
glycaemia/insulinaemia  in  type  2  diabetic  subjects,  have  been  recently  reviewed  in  a  number  of Tolerable Upper Intake Level of EPA, DHA and DPA 
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systematic reviews and meta-analyses (Balk et al., 2004; De Caterina et al., 2007; Farmer et al., 2001; 
Friedberg et al., 1998; Hartweg et al., 2008; 2009; Hendrich, 2010; MacLean et al., 2004; Montori et 
al., 2000).  
Doses of up to 5 g/day of n-3 LCPUFA given as triglycerides for 2-12 weeks do not appear to increase 
insulin requirements in subjects with type 1 diabetes, although the studies are small (De Caterina et 
al., 2007; Friedberg et al., 1998).  
With  respect  to  subjects  with  type  2  diabetes,  a  Cochrane  systematic  review  and  meta-analysis 
performed in 2001 (Farmer et al., 2001) on the effects of fish oil in subjects with type 2 diabetes on 
different outcomes, including those related to glucose homeostasis, was updated in 2008 and 2009 
(Hartweg  et  al.,  2008;  2009).  The  meta-analysis  by  Hartweg  et  al.  (2008)  included  23  trials 
(1,075 subjects, sample size range 8 to 418) where the majority of participants were male (age range 
21-85  years)  with  type  2  diabetes  of  5-10  years  duration  under  treatment  with  diet  or  oral 
hypoglycaemic  agents,  and  generally  with  no  diabetes-related  complications.  The  mean  dose  of 
n-3 LCPUFA was 3.5 g/day, ranged from 1.7 to 10 g/day (from 1.08 to 5.2 g/day of EPA and from 
0.3 to 4.8 g/day of DHA), and the mean duration of treatment was 8.9 weeks. The EPA and DHA 
were given mostly in combination (two intervention arms gave EPA only and one DHA only) and in 
capsules. In most cases, controls received similar amounts of fat from vegetable oils (olive, sunflower, 
linseed, corn, safflower, and flaxseed). Linoleic acid, non-fat placebo, a saline solution, or usual diet 
served as control in the remaining studies (n=5). A total of 15 trials (n=848 subjects) reported on 
HbA1c, of which only four lasted at least 12 weeks, which is the time normally required to detect 
differences in HbA1c, and 11 lasted at least eight weeks, which may only allow detection of major 
changes in blood glucose control. A total of 21 trials reported fasting glucose concentrations, and the 
results could be pooled for 16 studies (n=930 subjects). Results from six of the eight studies reporting 
on fasting insulin concentrations could also be pooled. Supplementation with n-3 LCPUFA did not 
significantly affect HbA1c, fasting glucose or insulin concentrations. Similar results were obtained 
when seven new trials with a mean dose of 2.4 g/day (range 0.8 to 4.8 g/day) and mean duration of 
24 weeks were added to the analyses (Hartweg et al., 2009). More recent studies are in line with these 
results (Hendrich, 2010).  
Galgani  et  al.  (2008)  reviewed  the  effects  of  n-3  LCPUFA  on  insulin  sensitivity  in  high-quality 
randomised intervention studies which used the euglycemic hyperinsulinemic clamp or the frequently 
sampled  intravascular  glucose  tolerance  test  while  controlling  for  the  energy  and  macronutrient 
composition  of  the  intervention  and  control  diets.  One  study  which  met  these  requirements  was 
published thereafter (Giacco et al., 2007). All studies used fish oil as a source of EPA and DHA and 
vegetable oils as control (olive oil, corn oil, safflower oil). Four studies (n=32 to 162) were conducted 
in  healthy  subjects  using  2.4  to  3.6 g/day  of  EPA  and  DHA  for  12-16  weeks.  No  effect  of 
n-3 LCPUFA on insulin sensitivity was observed compared to the control oils (olive oil, corn oil). 
Five studies (n= 10 to 26) recruited subjects with type 2 diabetes and used EPA and DHA at doses of 
1.8 to 5 g/day and vegetable oils (olive oil, corn oil, safflower oil) as controls for 3-24 weeks. Only 
the study providing the highest dose of n-3 LCPUFA (5 g/day containing about 2.1 g EPA, 3.5 g DHA 
and  0.3  g  DPA)  for  nine  weeks  (Mostad  et  al.,  2006)  reported  a  marginal  decrease  in  glucose 
utilisation during the euglycemic hyperinsulinaemic clamp in the fish oil group (n=13) compared to 
the maize oil group (n=14; p=0.049) in a small sample of subjects. No significant changes in HbA1c 
were observed in this and other longer-term studies described above.  
The Panel notes that human intervention studies which have controlled for fat intake generally do not 
show a differential effect of vegetable oils and supplemental fish oil at doses up to 5 g/day of EPA 
and  DHA  consumed  for  12  weeks  on  blood  glucose  control  in  diabetic  subjects,  or  on  insulin 
sensitivity in healthy or diabetic subjects.  
The Panel considers that supplemental intakes of EPA and DHA combined of up to 5 g/day consumed 
for up to 12 weeks do not significantly affect glucose homeostasis in healthy or diabetic subjects. The Tolerable Upper Intake Level of EPA, DHA and DPA 
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Panel  notes  that  the  data  available  are  insufficient  to  conclude  on  whether  the  same  doses 
administered mostly as EPA or mostly as DHA would have different effects on this outcome.  
3.3.  LDL-cholesterol concentrations in blood 
Several human intervention studies have addressed the effects of supplementation with n-3 LCPUFA 
on blood LDL-cholesterol concentrations. 
A meta-analysis of RCTs (Balk et al., 2006) pooled the results from 21 RCTs (about 8,000 subjects, 
37  intervention  arms)  conducted  in  healthy  subjects;  in  subjects  with  diabetes,  hypertension,  or 
dyslipidemia; or in subjects with cardiovascular disease. Studies using >6 g/day of EPA + DHA or 
lasting <4 weeks were excluded. Due to the high number of studies found in the literature, a minimum 
sample size of 12 subjects per each n-3 LCPUFA intervention arm was required for inclusion. Doses 
of  EPA  and  DHA  ranged  from  0.9  to  5.9  g/day  (from  fish  oil  or  food)  and  the  duration  of  the 
intervention was between 4 weeks and 2 years (17 studies lasted  6 months and 8 studies lasted  1 
year at doses  of about 3.4 g/day). Study design was considerably heterogeneous. Random effects 
model meta-analyses found a significant increase in LDL cholesterol of +0.155 mmol/L (95 % CI 
+0.078 mmol/L, +0.207 mmol/L) compared to the control oils. In the majority of the studies, changes 
in LDL cholesterol associated with EPA and DHA intakes were <5 %. Earlier studies reported the 
highest increases in LDL-cholesterol. The Panel notes that these changes in LDL-cholesterol were 
accompanied by a significant decrease in TG (−0.31 mmol/L; 95 % CI −0.37 mmol/L, −0.23 mmol/L) 
and  by  a  significant  increase  in  HDL-cholesterol  (+0.041 mmol/L;  95 %  CI  +0.021 mmol/L, 
+0.060 mmol/L), and that total blood cholesterol did not change significantly. Sensitivity analyses 
showed that dose of EPA and DHA and baseline concentrations of TG had a cumulative impact on the 
magnitude  of  changes  in  TG,  but  no  influence  on  changes  in  HDL  or  LDL  cholesterol,  which 
appeared to be dose-independent.  
Since hypertriglyceridaemia is often observed in type 2 diabetes and this population subgroup is 
already at higher risk for CVD, an increase in LDL-cholesterol concentrations resulting from the 
treatment of elevated TG concentrations could be of particular concern in diabetic subjects. In the 
meta-analyses by Hartweg et al., (2008; 2009) that are described in Section 3.2, the effects of EPA 
and  DHA  supplementation  on  LDL-cholesterol  concentrations  were  investigated  in  subjects  with 
type 2 diabetes. Most studies provided EPA and DHA in combination at doses up to 6 g/day. Out of 
the 30 RCTs considered, 27 reported on LDL-cholesterol, 24 (n=1,530) on TG, 23 (n=1,533) on total 
cholesterol, 22 (n=1,443) on HLD-cholesterol, nine (n=637) on VLDL, five (n=476) on apoproteins 
A1 and B, and four (n=443) assessed LDL particle size. Compared to placebo (mostly vegetable oils), 
n-3 LCPUFA supplementation significantly increased LDL-cholesterol concentrations by 3 % (mean 
increase=+0.08 mmol/L). This effect was only observed at doses of >2 g/day of n-3 LCPUFA and was 
accompanied  by  a  significant  reduction  in  blood  concentrations  of  TG  of  about  7 %  (mean 
reduction=0.17  mmol/L),  whereas  no  significant  effect  was  reported  on  the  remaining  outcomes 
related to blood lipids, including total cholesterol concentrations.  
A  recently  published  systematic  review  and  meta-analysis  of  RCTs  lasting  four  weeks  or  longer 
investigated whether these n-3 LCPUFA had different effects on blood lipids (Jacobson et al., 2012; 
Wei and Jacobson, 2011). Twelve studies used mostly DHA and four studies used mostly EPA. The 
control intervention in the studies using mostly DHA (from algal oils, 38 % DHA and 30 % saturated 
fatty acids, doses 0.7-3.0 g/day, mean=1.7 g/day) was either a control fat (olive oil, two studies) or a 
control diet, and lasted six weeks to three months (average seven weeks). In the studies comparing 
EPA (ethyl esters) to placebo or to a control intervention, the dose was always 1.8 g/day and EPA was 
given for three months to five years (average 12 weeks excluding the five-year study). The Panel 
notes that these studies may not have been appropriately controlled for other dietary components 
known to increase LDL-cholesterol concentrations (e.g. saturated fatty acids) and for the different Tolerable Upper Intake Level of EPA, DHA and DPA 
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dose range of DHA and EPA used. The Panel considers that these studies do not allow conclusions to 
be drawn on the effects of EPA or DHA, or on the effects of EPA vs. DHA, on LDL cholesterol.  
In the same systematic review and meta-analysis (Jacobson et al., 2012; Wei and Jacobson, 2011), six 
studies which directly compared EPA (ethyl esters,  >90 % EPA) with DHA (ethyl esters, >90 % 
DHA) used olive oil, safflower oil, corn oil or ALA as control fat, lasted 4-7 weeks, and administered 
EPA and DHA at doses between 2.3 and 4 g/day each. Control-adjusted changes in blood lipids were 
calculated for the EPA and DHA groups. DHA significantly increased LDL-cholesterol by 2.6 % 
compared to the control fat and by 3.3 % compared to EPA, which did not induce significant changes 
in LDL cholesterol (-0.7 %). The Panel notes that the observed increase in LDL cholesterol induced 
by DHA supplementation compared to the control fats was associated with a significant decrease in 
TG  (-22.4 %)  and  with  a  significant  increase  in  HDL-cholesterol  (+7.3 %),  and  that  non-HDL 
cholesterol was virtually not affected (-1.2 %). The Panel also notes that EPA supplementation did not 
have a significant effect on LDL- (-0.7 %) or HDL- (+1.4 %) cholesterol concentrations, and that 
these n-3 LCPUFAs appear to exert different effects on blood lipids.  
It has been suggested that n-3 LCPUFA may enhance transformation of TG-rich VLDL lipoproteins 
to  cholesterol-rich  LDL  lipoproteins  leading  to  a  decrease  in  fasting  TGs  and  to  an  increase  in 
LDL-cholesterol by increasing particle size rather than particle number. These changes do not appear 
to be associated with an increase in total cholesterol or apolipoprotein B (VKM, 2011).  
The Panel notes that supplemental intakes of EPA and DHA combined of 2-6 g/day, and supplemental 
intakes of mostly DHA of 2-4 g/day, increase blood concentrations of LDL-cholesterol by about 3 %, 
and that such increase is accompanied by a decrease in TG with no changes in total (or non-HDL) 
cholesterol concentrations. The Panel also notes that supplemental intakes of mostly EPA at doses up 
to 4 g/day have no significant effect on LDL cholesterol concentrations. The Panel considers that the 
small  increase  in  LDL-cholesterol  concentrations  associated  with  combined  EPA  and  DHA 
supplementation  or  with  DHA  supplementation  alone  at  the  doses  mentioned  above  may  not  be 
adverse in relation to CVD risk.  
3.4.  Markers of lipid peroxidation 
Enhanced oxidative stress and increased lipid peroxidation occurring either locally in the vessel wall 
or systemically have been implicated in the pathogenesis of atherosclerosis in humans, although it is 
uncertain and poorly characterised whether, and the extent to which, changes in different markers of 
lipid peroxidation may modulate the risk of cardiovascular diseases independently of traditional risk 
factors. 
Early observations linking DHA intake with increased lipid peroxidation and oxidative damage to 
cells and molecules in laboratory animals may have been confounded by the presence of primary and 
secondary oxidation products in supplements lacking antioxidants. This effect was indeed reversed 
when DHA was administered with supplemental vitamin E (IoM, 2005; VKM, 2011). 
The  majority  of  the  human  intervention  studies  considered  below  used  fish  oil  stabilised  with 
antioxidants,  but  some  studies  did  not  report  whether  sources  of  EPA,  DHA,  or  both,  contained 
antioxidants  or  not,  whereas  only  a  few  studies  reported  on  the  concentration  of  primary  and 
secondary oxidation products in the supplements administered. The Panel notes that the addition of 
antioxidants to food supplements containing n-3 LCPUFA to ensure product stability appears to be 
optional (GOED (Global Organisation for EPA and DHA Omega-3s), 2012). Tolerable Upper Intake Level of EPA, DHA and DPA 
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3.4.1.  F2-isoprostanes 
Some  F2-isoprostanes  assessed  in  urine  or  plasma  (i.e.  by  immunometric  assays  or  by 
mass-spectrometry) are reliable measures of in vivo lipid peroxidation. F2-isoprostanes are increased 
in  association  with  a  number  of  atherosclerotic  risk  factors,  including  cigarette  smoking, 
hypercholesterolaemia,  diabetes  mellitus  and  obesity,  among  others.  Also  a  reduction  in 
cardiovascular  risk  factors  is  associated  with  a  decrease  in  F2-isoprostanes  formation  in  humans. 
However, the potential contribution of these compounds to the pathophysiology of vascular damage 
and  atherosclerosis  has  not  yet  been  defined  (Minuz  et  al.,  2006; Morrow, 2005; Patrignani and 
Tacconelli, 2005). 
A recent review identified nine controlled human intervention studies which used n-3 LCPUFA-rich 
oils  stabilised  with  antioxidants,  and  mostly  vegetable  oils  as  control  (olive,  maize,  sunflower, 
safflower or soy oil), and reported on plasma or urinary F2-isoprostanes (VKM, 2011). An additional 
study of more recent publications was identified by the Panel (Mas et al., 2010). Three studies were 
conducted  in  newborns  (following  maternal  supplementation  from  20  weeks  of  gestation  until 
delivery with 4 g/day EPA and DHA from fish oil) (Barden et al., 2004), pre-term infants (EPA and 
DHA were incorporated to the pre-term formula; 5.25-8.75 mg/100 mL of formula) (Stier et al., 2001) 
or children with familial hypercholesterolaemia (9-19 years, 1.2 g/day DHA) (Engler et al., 2004). 
The remaining studies had recruited a variety of adults who were either healthy (e.g. young men, post-
menopausal women) or with various disease conditions (e.g. obesity, non insulin-dependent diabetes 
mellitus, hypertension, end-stage renal disease), and used either DHA alone (800 mg-4 g/day), EPA 
alone (1.6-4 g/day) or EPA and DHA in combination as fish oil (2-4 g/day) for three to six weeks. The 
studies of longer duration (six weeks) used the highest doses of EPA and DHA, both alone and in 
combination. Half of the studies reported a significant decrease in plasma or urinary concentrations of 
F2-isoprostanes in the n-3 LCPUFA group compared to controls (Barden et al., 2004; Higdon et al., 
2000; Mas et al., 2010; Mori et al., 2000; 2003), whereas the remaining studies did not observe 
significant changes between groups (Engler et al., 2004; Himmelfarb et al., 2007; Stier et al., 2001; 
Tholstrup  et  al.,  2004;  Wu  et  al.,  2006).  The  Panel  notes  that  the  concentration  of  primary  and 
secondary oxidation products in the oils used measured as peroxide value (PV) and anisidine value 
(AV) were reported only in a few studies. 
The  Panel  considers  that  supplemental  intakes  of  EPA  and  DHA  consumed  either  alone  or  in 
combination at doses up to about 4 g/day for six weeks do not induce lipid peroxidation as assessed 
by F2-isoprostanes.  
3.4.2.  Oxidation of LDL particles 
As for F2-isoprostanes, oxidation of LDL particles has been associated with an increased risk of CVD 
in  some  studies,  but  the  causality  of  such  association  has  not  been  established.  Oxidised  LDL 
particles can be measured in blood directly by immunological methods, and their susceptibility to 
oxidation may be measured ex vivo after challenge with different pro-oxidant agents. The Panel notes 
that the latter is not an appropriate method to assess in vivo LDL peroxidation.    
Susceptibility of LDL to oxidation has been reported to be increased, decreased or unchanged during 
consumption of EPA and DHA from either fish oil or as ethyl esters, in a number of studies. Whereas 
an  increased  susceptibility  of  LDL  to  oxidation  has  been  reported  in  some  short-term  studies 
(4-6 weeks),  longer-term  interventions  (6-16  weeks)  show  no  effect  compared  to  control  (mostly 
vegetable) oils at doses up to about 5 g/day (VKM, 2011).  
Two studies in which the diet was supplemented with salmon containing EPA and DHA 1.5 g/day and 
2.9 g/day (Seierstad et al., 2005) or herring containing EPA and DHA 1.2 g/day (Lindqvist et al., 
2009) did not show an effect of the intervention on plasma oxidised LDL concentrations compared to 
controls.  Tolerable Upper Intake Level of EPA, DHA and DPA 
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The Panel considers that  supplemental intakes of EPA and DHA combined at doses up to about 
5 g/day consumed for up to 16 weeks do not induce sustained oxidative changes in circulating LDL 
particles. 
3.4.3.  Other markers of lipid peroxidation 
Supplementation with EPA and DHA at doses up to 4.5 g/day has not been shown to affect other 
measures  traditionally  used  to  assess  lipid  peroxidation,  such  as  thiobarbituric  acid  reactive 
substances  (TBARS),  malondialdehyde  (MDA),  conjugated  diens  or  lipid  hydroperoxides  (VKM, 
2011). The Panel notes that these are not reliable markers of in vivo lipid peroxidation (EFSA Panel 
on Dietetic Products Nutrition and Allergies (NDA), 2011). 
3.4.4.  Conclusion 
The  Panel  considers  that  supplemental  intakes  of  EPA  and  DHA  consumed  either  alone  or  in 
combination  at  doses  up  to  about  5 g/day  for  up  to  16  weeks  do  not  induce  changes  in  lipid 
peroxidation which might raise concern in relation to CVD risk as long as the oxidative stability of 
these n-3 LCPUFAs is guaranteed.  
3.5.  Immune function 
Immunosuppression,  if  sustained,  may  increase  the  risk  of  infections.  There  are  no  human 
intervention studies available which have investigated the effects of n-3 LCPUFA supplementation on 
the risk of infections in vivo. There is some indication, from ex vivo and in vitro studies performed in 
peripheral white blood cells of human subjects consuming n-3 LCPUFA, that EPA and DHA may 
decrease the expression of cytokines and the proliferation of peripheral white blood cells at doses as 
low as 0.9 g/day EPA and 0.6 g/day DHA consumed as fish oil for 6-8 weeks (reviewed in IoM, 
2005). However, the clinical relevance of these changes in vivo is unknown.  
Chronic and/or inappropriate activation of inflammatory responses (innate immunity) can also lead to 
disease. However, there is no information available on the effect of high intakes of n-3 LCPUFA on 
the risk of chronic diseases of inflammatory origin. Some markers of the so-called low-grade systemic 
(e.g. high-sensitivity C-reactive protein, and some cytokines) and vascular (e.g., sICAM-1, VCAM-1, 
and E-selectin) inflammation have been associated with an increased risk of cardiovascular events in 
healthy and high-risk subjects. However, there is no evidence that changes induced by diet or drugs in 
any of these markers modify the risk of disease per se. Most of the intervention studies available 
(reviewed in VKM, 2011) which report on the effects of EPA and DHA on markers of systemic and 
vascular inflammation are small and generally not designed for that purpose. Although an increase in 
E-selectin and/or in sVCAM-1 has been reported in some studies at doses of EPA and DHA of about 
5 g/day, a recent meta-analysis of 18 randomised controlled trials found no effect of n-3 LCPUFA 
supplementation (dose 0.272 to 6.6 g/day) on these markers of vascular inflammation and a significant 
decrease in sICAM-1 (Yang et al., 2012). The majority of the studies report either no effect or a 
decrease in systemic markers of inflammation, including  hs-CRP and TNF-alpha (Bloomer et al., 
2009; VKM, 2011).  
The Panel considers that supplemental intakes of EPA and DHA up to about 5 g/day are unlikely to 
induce changes in immune functions which might raise concern in relation to the risk of infections or 
inappropriate  activation  of  inflammatory  responses.  The  Panel  notes  that  the  data  available  are 
insufficient to conclude on whether the same doses administered mostly as EPA or mostly as DHA 
would have different effects on this outcome.  Tolerable Upper Intake Level of EPA, DHA and DPA 
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4.  Derivation of a tolerable upper intake level (UL) 
The available data are not sufficient to establish a tolerable upper intake level for n-3 LCPUFA 
(DHA, EPA, and DPA, individually or combined) for any population group. 
5.  Characterisation of the risk 
Mean  dietary  intake  estimates  of  n-3  LCPUFA  (EPA,  DHA    DPA)  from  foods  in  European 
populations are up to 400-500 mg/day in adults and up to 324 mg/day in children. When supplements 
were included, or when only high consumers of fatty fish were considered, reported intakes in EU 
populations  can  be  much  higher,  for  example  up  to  2,570-2,700  mg/day  in  adults  and  up  to 
400-600 mg/day in children (95 % percentile, 1,400-1,700 mg/day). The Panel notes that the studies 
reporting on high consumers of fish did not consider n-3 LCPUFA intakes from food supplements. 
The Panel notes that at observed intake levels, consumption of n-3 LCPUFA has not been associated 
with adverse effects in healthy children or adults.  
The Panel considers that supplemental intakes of EPA and DHA combined at doses up to 5 g/day, and 
supplemental  intakes  of  EPA  alone  up  to  1.8  g/day,  do  not  raise  safety  concerns  for  the  adult 
population. Limited data are available on the effects of long-term supplementation with these n-3 
LCPUFAs at higher doses. The Panel also notes that observed intakes of EPA and DHA from food 
and  food  supplements  in  European  populations  are  generally  below  these  amounts.  Dietary 
recommendations  for  EPA  and  DHA  based  on  CVD  risk  considerations  for  European  adults  are 
between 250 and 500 mg/day. There are no specific recommendations for EPA. 
The Panel also considers that supplemental intakes of DHA alone up to about 1 g/day do not raise 
safety concerns for the general population. Limited data are available on the effects of long-term 
supplementation  with  DHA  alone  at  higher  doses.  The  Panel  notes  that  specific  dietary 
recommendations for DHA for European adults and children are well below this amount.  
No data are available for DPA when consumed alone. The Panel notes that in the majority of the 
human studies considered, fish oils, which also contained DPA in generally unknown (but relatively 
low) amounts, were the source of EPA and DHA.  No dietary recommendations have been made 
specifically for DPA. 
CONCLUSIONS  
The Panel concludes that the available data are not sufficient to establish a tolerable upper intake 
level for n-3 LCPUFA (DHA, EPA, and DPA, individually or combined) for any population group.  
The Panel considers that supplemental intakes of EPA and DHA combined at doses up to 5 g/day, and 
supplemental  intakes  of  EPA  alone  up  to  1.8  g/day,  do  not  raise  safety  concerns  for  the  adult 
population. The Panel also considers supplemental intakes of DHA alone up to about 1 g/day do not 
raise safety concerns for the general population. No data are available for DPA when consumed alone. 
The Panel notes that in the majority of the human studies considered, fish oils, which also contained 
DPA in generally unknown (but relatively low) amounts, were the source of EPA and DHA.  
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APPENDICES 
A.  INTAKE OF LONG-CHAIN N-3 FATTY ACIDS (MG/DAY) AMONG ADULTS IN EUROPEAN COUNTRIES 
LCn-3 
PUFA 
Nutrient 
source  Sex  Country  Reference  Dietary method  n 
Age 
min 
 
Age 
max 
Population / Fortified foods included 
or excluded  mean  median  P75  P95 
EPA  Food  Women  Belgium 
(Sioen et al., 
2006)  2-day record  641  18 
 
39 
Data collected only on women in Ghent, 
Flanders  77.8  14.0 
 
427.7 
     
Denmark 
(Joensen  et 
al., 2010) 
food frequency 
questionnaire  29,017  50 
 
64 
Data of the Danish Diet, Cancer and 
Health cohort study, collected on 
volunteers living in Copenhagen or 
Aarhus. Recruitment 1993-1997 
 
150.0  230.0 
 
     
France 
(Bemrah  et 
al., 2009) 
food frequency 
questionnaire  344  18 
 
44 
French high seafood consumers 
(CALIPSO study). N-3 consumption 
from seafood (not from the total diet)   432.0 
     
           
630  18 
 
64 
French high seafood consumers 
(CALIPSO study). N-3 consumption 
from seafood (not from the total diet)   448.0 
     
EPA  Food  Men  Denmark 
(Joensen  et 
al., 2010) 
food frequency 
questionnaire  24,786  50 
 
64 
Data of the Danish Diet, Cancer and 
Health cohort study, collected on 
volunteers living in Copenhagen or 
Aarhus. Recruitment 1993-1997 
 
180.0  270.0 
 
     
France 
(Bemrah  et 
al., 2009) 
food frequency 
questionnaire  243  18 
 
64 
French high seafood consumers 
(CALIPSO study). N-3 consumption 
from seafood (not from the total diet)   456.0 
     
EPA  Food 
Men 
and 
women  France 
(Guevel  et 
al., 2008) 
food frequency 
questionnaire  n.a.  18  >  65 
French high seafood consumers 
(CALIPSO study). First quintile of EPA-
DHA intake  141.0  140.0 
   
       
(Guevel  et 
al., 2008) 
food frequency 
questionnaire  n.a.  18  >  65 
French high seafood consumers 
(CALIPSO study).Fifth quintile of EPA-
DHA intake  991.0  858.0 
   
       
(Bemrah  et 
al., 2009) 
food frequency 
questionnaire  126  65  >  65 
French high seafood consumers 
(CALIPSO study). N-3 consumption 
from seafood (not from the total diet)   467.0 
     
     
Spain 
(Amiano  et 
al., 2001) 
Diet history 
questionnaire 
(previous year)  26  35 
 
65 
Occasional fish consumers (<31 g/d). 
Adjusted for energy intake. Data on n-3 
fatty acid intake collected in the EPIC 
cohort of Gipuzkoa (Basque Country)  50.0 
     
           
24  35 
 
65 
Low fish consumers (32-64 g/d). 
Adjusted for energy intake. Data on n-3 
fatty acid intake collected in the EPIC 
cohort of Gipuzkoa (Basque Country)  130.0 
     Tolerable Upper Intake Level of EPA, DHA and DPA 
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LCn-3 
PUFA 
Nutrient 
source  Sex  Country  Reference  Dietary method  n 
Age 
min 
 
Age 
max 
Population / Fortified foods included 
or excluded  mean  median  P75  P95 
EPA  Food 
Men 
and 
women  Spain 
(Amiano  et 
al., 2001) 
Diet history 
questionnaire 
(previous year)  27  35 
 
65 
Moderate fish consumers (65-115 g/d). 
Adjusted for energy intake. Data on n-3 
fatty acid intake collected in the EPIC 
cohort of Gipuzkoa (Basque Country)  210.0 
     
           
25  35 
 
65 
High fish consumers (>115 g/d). 
Adjusted for energy intake. Data on n-3 
fatty acid intake collected in the EPIC 
cohort of Gipuzkoa (Basque Country)  320.0 
     
EPA  n.a.  Women  Finland 
(Suominen-
Taipale  et 
al., 2010) 
food frequency 
questionnaire  166  n.a.     n.a. 
Finnish maritime and freshwater area 
fishermen, their wives and other family 
members of a sub-group (living near 
Helsinki) of the Fishermen Study 
population. Mean age of the full study 
(n=1410): 47 y (SE: 0,5) for men, 46 
(SE: 0,5) for women.  200.0          
     
France 
(Astorg  et 
al., 2004) 
at least ten 24-hour 
recalls  2,785  35  >  35 
Data from the Su.Vi.Max cohort Study 
(inclusion in 1994-19695, follow-up of 8 
years), collected from at least ten 24-hour 
recalls over a period of 2.5 years, 
between the inclusion and 1998. Age at 
inclusion: 45-63 y (men), 35-63 y 
(women)  117.8  91.4 
 
308.5 
EPA  n.a.  Men  Finland 
(Suominen-
Taipale  et 
al., 2010) 
food frequency 
questionnaire  142  n.a. 
 
n.a. 
Finnish maritime and freshwater area 
fishermen, their wives and other family 
members of a sub-group (living near 
Helsinki) of the Fishermen Study 
population. Mean age of the full study 
(n=1410): 47 y (SE: 0,5) for men, 46 
(SE: 0,5) for women.  300.0 
     
     
France 
(Astorg  et 
al., 2004) 
at least ten 24-hour 
recalls  2,099  45  >  45 
Data from the Su.Vi.Max cohort Study 
(inclusion in 1994-19695, follow-up of 8 
years), collected from at least ten 24-hour 
recalls over a period of 2.5 years, 
between the inclusion and 1998. Age at 
inclusion: 45-63 y (men), 35-63 y 
(women)  149.9  119.6 
 
375.1 
EPA 
Food and 
supplements  Women 
United-
Kingdom 
(Welch et al., 
2010) 
7-day record (24-h 
recall and 6-day 
diary)  6258  39     78  Fish-eaters in the EPIC-Norfolk cohort  110.0          
EPA 
Food and 
supplements  Men 
United-
Kingdom 
(Welch et al., 
2010) 
7-day record (24-h 
recall and 6-day 
diary)  5,952  39 
 
78  Fish-eaters in the EPIC-Norfolk cohort  130.0 
     Tolerable Upper Intake Level of EPA, DHA and DPA 
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LCn-3 
PUFA 
Nutrient 
source  Sex  Country  Reference  Dietary method  n 
Age 
min 
 
Age 
max 
Population / Fortified foods included 
or excluded  mean  median  P75  P95 
EPA 
Food and 
supplements 
Men 
and 
women  Norway 
(Johansson 
et al., 1998) 
food frequency 
questionnaire  3,144  16     79  National survey NORKOST 1997  330.0          
DPA  Food  Women  Belgium 
(Sioen et al., 
2006)  2-day record  641  18     39 
Data collected only on women in Ghent, 
Flanders  25.3  11.7     100.2 
         Denmark 
(Joensen et 
al., 2010) 
food frequency 
questionnaire  29,017  50     64 
Data of the Danish Diet, Cancer and 
Health cohort study, collected on 
volunteers living in Copenhagen or 
Aarhus. Recruitment 1993-1997     60.0  90.0    
         France 
(Bemrah et 
al., 2009) 
food frequency 
questionnaire  344  18     44 
French high seafood consumers 
(CALIPSO study). N-3 consumption 
from seafood (not from the total diet)   126.0          
                  630  18     64 
French high seafood consumers 
(CALIPSO study). N-3 consumption 
from seafood (not from the total diet)   127.0          
DPA  Food  Men  Denmark 
(Joensen et 
al., 2010) 
food frequency 
questionnaire  24,786  50     64 
Data of the Danish Diet, Cancer and 
Health cohort study, collected on 
volunteers living in Copenhagen or 
Aarhus. Recruitment 1993-1997     80.0  100.0    
         France 
(Bemrah et 
al., 2009) 
food frequency 
questionnaire  243  18     64 
French high seafood consumers 
(CALIPSO study). N-3 consumption 
from seafood (not from the total diet)   129.0          
DPA  Food 
Men 
and 
Women  France 
(Bemrah et 
al., 2009) 
food frequency 
questionnaire  126  65  >  65 
French high seafood consumers 
(CALIPSO study). N-3 consumption 
from seafood (not from the total diet)   125.0          
DPA  n.a.  Women  France 
(Astorg et 
al., 2004) 
at least ten 24-hour 
recalls  2,785  35  >  35 
Data from the Su.Vi.Max cohort Study 
(inclusion in 1994-19695, follow-up of 8 
years), collected from at least ten 24-hour 
recalls over a period of 2.5 years, 
between the inclusion and 1998. Age at 
inclusion: 45-63 y (men), 35-63 y 
(women)  55.9  50.2     109.1 
DPA  n.a.  Men  France 
(Astorg et 
al., 2004) 
at least ten 24-hour 
recalls  2,099  45  >  45 
Data from the Su.Vi.Max cohort Study 
(inclusion in 1994-19695, follow-up of 8 
years), collected from at least ten 24-hour 
recalls over a period of 2.5 years, 
between the inclusion and 1998. Age at 
inclusion: 45-63 y (men), 35-63 y 
(women)  74.8  68.2     138.4 
DPA 
Food and 
supplements 
Men 
and 
Women  Norway 
(Johansson 
et al., 1998) 
food frequency 
questionnaire  3,144  16     79  National survey NORKOST 1997  70.0          Tolerable Upper Intake Level of EPA, DHA and DPA 
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LCn-3 
PUFA 
Nutrient 
source  Sex  Country  Reference  Dietary method  n 
Age 
min 
 
Age 
max 
Population / Fortified foods included 
or excluded  mean  median  P75  P95 
DHA  Food  Women  Belgium 
(Sioen et al., 
2006)  2-day record  641  18     39 
Data collected only on women in Ghent, 
Flanders  131.2  42.5     647.1 
     
Denmark 
(Joensen  et 
al., 2010) 
food frequency 
questionnaire  29,017  50 
 
64 
Data of the Danish Diet, Cancer and 
Health cohort study, collected on 
volunteers living in Copenhagen or 
Aarhus. Recruitment 1993-1997 
 
360.0  520.0 
 
     
France 
(Bemrah  et 
al., 2009) 
food frequency 
questionnaire  344  18 
 
44 
French high seafood consumers 
(CALIPSO study). N-3 consumption 
from seafood (not from the total diet)   757.0 
     
           
630  18 
 
64 
French high seafood consumers 
(CALIPSO study). N-3 consumption 
from seafood (not from the total diet)   776.0 
     
DHA  Food  Men  Denmark 
(Joensen  et 
al., 2010) 
food frequency 
questionnaire  24,786  50 
 
64 
Data of the Danish Diet, Cancer and 
Health cohort study, collected on 
volunteers living in Copenhagen or 
Aarhus. Recruitment 1993-1997 
 
430.0  630.0 
 
     
France 
(Bemrah  et 
al., 2009) 
food frequency 
questionnaire  243  18 
 
64 
French high seafood consumers 
(CALIPSO study). N-3 consumption 
from seafood (not from the total diet)   797.0 
     
DHA  Food 
Men 
and 
women  France 
(Guevel  et 
al., 2008) 
food frequency 
questionnaire  n.a.  18  >  65 
French high seafood consumers 
(CALIPSO study). First quintile of EPA-
DHA intake  251.0  260.0 
   
     
France 
(Guevel  et 
al., 2008) 
food frequency 
questionnaire  n.a.  18  >  65 
French high seafood consumers 
(CALIPSO study). Fifth quintile of EPA-
DHA intake  1,709.0  1,434.0 
   
       
(Bemrah  et 
al., 2009) 
food frequency 
questionnaire  126  65  >  65 
French high seafood consumers 
(CALIPSO study). N-3 consumption 
from seafood (not from the total diet)   819.0 
     
     
Spain 
(Amiano  et 
al., 2001) 
Diet history 
questionnaire 
(previous year)  26  35 
 
65 
Occasional fish consumers (<31 g/d). 
Adjusted for energy intake. Data on n-3 
fatty acid intake collected in the EPIC 
cohort of Gipuzkoa (Basque Country)  190.0 
     
           
24  35 
 
65 
Low fish consumers (32-64 g/d). 
Adjusted for energy intake. Data on n-3 
fatty acid intake collected in the EPIC 
cohort of Gipuzkoa (Basque Country)  440.0 
     
           
27  35 
 
65 
Moderate fish consumers (65-115 g/d). 
Adjusted for energy intake. Data on n-3 
fatty acid intake collected in the EPIC 
cohort of Gipuzkoa (Basque Country)  580.0 
     Tolerable Upper Intake Level of EPA, DHA and DPA 
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LCn-3 
PUFA 
Nutrient 
source  Sex  Country  Reference  Dietary method  n 
Age 
min 
 
Age 
max 
Population / Fortified foods included 
or excluded  mean  median  P75  P95 
DHA  Food 
Men 
and 
women  Spain 
(Amiano  et 
al., 2001) 
Diet history 
questionnaire 
(previous year)  25  35 
 
65 
High fish consumers (>115 g/d). 
Adjusted for energy intake. Data on n-3 
fatty acid intake collected in the EPIC 
cohort of Gipuzkoa (Basque Country)  850.0 
     
DHA  n.a.  Women  Finland 
(Suominen-
Taipale  et 
al., 2010) 
food frequency 
questionnaire  166  n.a.     n.a. 
Finnish maritime and freshwater area 
fishermen, their wives and other family 
members of a sub-group (living near 
Helsinki) of the Fishermen Study 
population. Mean age of the full study 
(n=1410): 47 y (SE: 0,5) for men, 46 
(SE: 0,5) for women.  600.0          
     
France 
(Astorg  et 
al., 2004) 
at least ten 24-hour 
recalls  2,785  35  >  35 
Data from the Su.Vi.Max cohort Study 
(inclusion in 1994-19695, follow-up of 8 
years), collected from at least ten 24-hour 
recalls over a period of 2.5 years, 
between the inclusion and 1998. Age at 
inclusion: 45-63 y (men), 35-63 y 
(women)  225.9  177.0 
 
574.2 
DHA  n.a.  Men  Finland 
(Suominen-
Taipale  et 
al., 2010) 
food frequency 
questionnaire  142  n.a. 
 
n.a. 
Finnish maritime and freshwater area 
fishermen, their wives and other family 
members of a sub-group (living near 
Helsinki) of the Fishermen Study 
population. Mean age of the full study 
(n=1410): 47 y (SE: 0,5) for men, 46 
(SE: 0,5) for women.  700.0 
     
     
France 
(Astorg  et 
al., 2004) 
at least ten 24-hour 
recalls  2,099  45  >  45 
Data from the Su.Vi.Max cohort Study 
(inclusion in 1994-19695, follow-up of 8 
years), collected from at least ten 24-hour 
recalls over a period of 2.5 years, 
between the inclusion and 1998. Age at 
inclusion: 45-63 y (men), 35-63 y 
(women)  272.6  221.3 
 
668.4 
DHA 
Food and 
supplements  Women 
United-
Kingdom 
(Welch et al., 
2010) 
7-day record (24-h 
recall and 6-day 
diary)  6258  39     78  Fish-eaters in the EPIC-Norfolk cohort  150.0          
DHA 
Food and 
supplements  Men 
United-
Kingdom 
(Welch et al., 
2010) 
7-day record (24-h 
recall and 6-day 
diary)  5,952  39 
 
78  Fish-eaters in the EPIC-Norfolk cohort  190.0 
     
DHA 
Food and 
supplements 
Men 
and 
women  Norway 
(Johansson 
et al., 1998) 
food frequency 
questionnaire  3,144  16     79  National survey NORKOST 1997  490.0          Tolerable Upper Intake Level of EPA, DHA and DPA 
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LCn-3 
PUFA 
Nutrient 
source  Sex  Country  Reference  Dietary method  n 
Age 
min 
 
Age 
max 
Population / Fortified foods included 
or excluded  mean  median  P75  P95 
EPA+ 
DHA  Food  Women  Belgium 
(Sioen et al., 
2010) 
food frequency 
questionnaire  19  18     39 
Non-consumers of n-3 foods and 
supplements. Data collected from a 
convenience sample (relatives, friends 
and colleagues) of women living in 
Flanders  181.0  118.0       
           
(Sioen et al., 
2006)  2-day record  641  18     39 
Data collected only on women in Ghent, 
Flanders  208.9  54.1     1,115.4 
     
The 
Netherlands 
(van Rossum 
et al., 2011) 
two non-
consecutive 24-
hour dietary recalls  347  19     30  National Dutch survey 2007-2010     75.0  133.0  285.0 
                  351  31     50  National Dutch survey 2007-2010     89.0  155.0  330.0 
                  353  51     69  National Dutch survey 2007-2010     107.0  185.0  388.0 
EPA+ 
DHA  Food  Men 
The 
Netherlands 
(van Rossum 
et al., 2011) 
two non-
consecutive 24-
hour dietary recalls  356  19     30  National Dutch survey 2007-2010     77.0  139.0  305.0 
                  348  31     50  National Dutch survey 2007-2010     95.0  169.0  364.0 
                  351  51     69  National Dutch survey 2007-2010     110.0  194.0  414.0 
EPA+ 
DHA  Food 
Men 
and 
women  France 
(Guevel et 
al., 2008) 
food frequency 
questionnaire  n.a.  18  >  65 
French high seafood consumers 
(CALIPSO study). First quintile of EPA-
DHA intake  392.0  405.0       
                  n.a.  18  >  65 
French high seafood consumers 
(CALIPSO study). Fifth quintile of EPA-
DHA intake  2,700.0  2,324.0       
EPA+ 
DHA 
Food 
(without 
fortified 
food)  Women  Germany 
(Bauch et al., 
2006) 
Dietary history 
(last 4 weeks)  181  18     24  National German survey 1998  126.6  83.9     367.8 
                  396  25     34  National German survey 1998  167.4  121.2     501.0 
                  399  35     44  National German survey 1998  196.6  147.2     471.8 
           
319  45     54  National German survey 1998  207.1  160.3     578.3 
                  369  55     64  National German survey 1998  218.9  172.4     560.1 
                  408  65     79  National German survey 1998  199.9  158.4     556.3 
EPA+ 
DHA 
Food 
(without 
fortified 
food)  Men  Germany 
(Bauch et al., 
2006) 
Dietary history 
(last 4 weeks)  189  18     24  National German survey 1998  232.1  153.9     790.3 
                  412  25     34  National German survey 1998  212.0  161.7     553.2 
                  411  35     44  National German survey 1998  238.3  181.8     643.5 
                  321  45     54  National German survey 1998  295.0  216.5     826.6 
                  353  55     64  National German survey 1998  274.4  195.1     794.5 Tolerable Upper Intake Level of EPA, DHA and DPA 
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LCn-3 
PUFA 
Nutrient 
source  Sex  Country  Reference  Dietary method  n 
Age 
min 
 
Age 
max 
Population / Fortified foods included 
or excluded  mean  median  P75  P95 
EPA+ 
DHA 
Food 
(without 
fortified 
food)  Men  Germany 
(Bauch et al., 
2006) 
Dietary history 
(last 4 weeks)  271  65     79  National German survey 1998  277.7  204.1     668.3 
EPA+ 
DHA 
Food and 
supplements  Women  Belgium 
(Sioen et al., 
2010) 
food frequency 
questionnaire  5  18     39 
Breasfeeding women. Data collected 
from a convenience sample (relatives, 
friends and colleagues) of women living 
in Flanders  299.0  205.0       
                  18  18     39 
Pregnant women. Convenience sample, 
in Flanders  328.0  232.0       
                  19  18     39 
Supplement users. Convenience sample, 
in Flanders  1,067.0  998.0       
                  395  18     39 
Consumers of n-3 foods. Convenience 
sample, in Flanders  281.0  209.0       
                  414  18     39 
Total population. Convenience sample, 
in Flanders  276.0  199.0       
     
The 
Netherlands 
(van Rossum 
et al., 2011) 
two non-
consecutive 24-
hour dietary recalls  347  19     30  National Dutch survey 2007-2010     76.0  133.0  296.0 
                  351  31     50  National Dutch survey 2007-2010     100.0  189.0  488.0 
           
353  51     69  National Dutch survey 2007-2010     133.0  264.0  611.0 
EPA+ 
DHA 
Food and 
supplements  Men 
The 
Netherlands 
(van Rossum 
et al., 2011) 
two non-
consecutive 24-
hour dietary recalls  356  19     30  National Dutch survey 2007-2010     75.0  137.0  312.0 
                  348  31     50  National Dutch survey 2007-2010     97.0  179.0  416.0 
                  351  51     69  National Dutch survey 2007-2010     131.0  239.0  513.0 
EPA+ 
DHA 
Food and 
supplements 
Men 
and 
women  Ireland 
(Leite et al., 
2010)  7-day record  1097  18     64 
Non under-reporters. North/South Ireland 
food consumption survey  275.0  124.0     1,147.0 
           
424  18     35 
Non under-reporters. North/South Ireland 
food consumption survey  187.0  99.0     825.0 
                  422  36     50 
Non under-reporters. North/South Ireland 
food consumption survey  297.0  133.0     1,160.0 
                  251  51     64 
Non under-reporters. North/South Ireland 
food consumption survey  386.0  179.0     1,278.0 Tolerable Upper Intake Level of EPA, DHA and DPA 
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LCn-3 
PUFA 
Nutrient 
source  Sex  Country  Reference  Dietary method  n 
Age 
min 
 
Age 
max 
Population / Fortified foods included 
or excluded  mean  median  P75  P95 
EPA+ 
DHA  Supplements  Women  Austria 
(Elmadfa et 
al., 2009) 
Quantitative 
consumption 
frequency 
questionnaire  6  18     65 
Data collected on consumption of dietary 
supplements among 282 adults in all 
Austria (77 supplements users)     268.0  738.0    
EPA+ 
DHA  Supplements  Men  Austria 
(Elmadfa et 
al., 2009) 
Quantitative 
consumption 
frequency 
questionnaire  5  18     65 
Data collected on consumption of dietary 
supplements among 282 adults in all 
Austria (77 supplements users)     557.0  1,000.0    
EPA+ 
DPA+ 
DHA  n.a.  Women  France 
(Astorg  et 
al., 2004) 
at least ten 24-hour 
recalls  2785  35  >  35 
Data from the Su.Vi.Max cohort Study 
(inclusion in 1994-19695, follow-up of 8 
years), collected from at least ten 24-hour 
recalls over a period of 2.5 years, 
between the inclusion and 1998. Age at 
inclusion: 45-63 y (men), 35-63 y 
(women)  399.6  320.6     980.2 
EPA+ 
DPA+ 
DHA  n.a.  Men  France 
(Astorg  et 
al., 2004) 
at least ten 24-hour 
recalls  2785  45  >  45 
Data from the Su.Vi.Max cohort Study 
(inclusion in 1994-19695, follow-up of 8 
years), collected from at least ten 24-hour 
recalls over a period of 2.5 years, 
between the inclusion and 1998. Age at 
inclusion: 45-63 y (men), 35-63 y 
(women)  497.3  408.3     1,159.3 
EPA+ 
DPA+ 
DHA 
Food and 
supplements  Women  Norway 
(Johansson 
et al., 1998) 
food frequency 
questionnaire  406  16 
 
79 
First quartile of long chain n-3 fatty 
acids. National survey NORKOST 1997  130.0 
     
           
406  16 
 
79 
Fourth quartile of long chain n-3 fatty 
acid intake. National survey NORKOST 
1997  1,730.0 
      EPA+ 
DPA+ 
DHA 
Food and 
supplements  Men  Norway 
(Johansson 
et al., 1998) 
food frequency 
questionnaire  379  16 
 
79 
First quartile of long chain n-3 fatty 
acids. National survey NORKOST 1997  190.0 
     
           
378  16 
 
79 
Fourth quartile of long chain n-3 fatty 
acid intake. National survey NORKOST 
1997  2,570.0 
      EPA+ 
DPA+ 
DHA 
Food and 
supplements 
Men 
and 
women  Norway 
(Johansson 
et al., 1998) 
food frequency 
questionnaire  3144  16 
 
79  National survey NORKOST 1997  890.0 
     Tolerable Upper Intake Level of EPA, DHA and DPA 
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LCn-3 
PUFA 
Nutrient 
source  Sex  Country  Reference  Dietary method  n 
Age 
min 
 
Age 
max 
Population / Fortified foods included 
or excluded  mean  median  P75  P95 
LC n-3 
PUFA 
Food 
(including 
fish oil)  Women  Iceland 
(Steingrímsd
óttir et al., 
2003)  24-hour recall 
n.a. (total 
female 
sample 
15-80 y: 
662)  20     39  National Icelandic survey  300.0          
                 
n.a. (total 
female 
sample 
15-80 y: 
662)  40     59  National Icelandic survey  600.0          
                 
n.a. (total 
female 
sample 
15-80 y: 
662)  60     80  National Icelandic survey  900.0          
LC n-3 
PUFA 
food 
(including 
fish oil)  Men  Iceland 
(Steingrímsd
óttir et al., 
2003)  24-hour recall 
n.a. (total 
male 
sample 
15-80 y: 
580)  20     39  National Icelandic survey  700.0          
                 
n.a. (total 
male 
sample 
15-80 y: 
580)  40     59  National Icelandic survey  1,100.0          
                 
n.a. (total 
male 
sample 
15-80 y: 
580)  60     80  National Icelandic survey  1,300.0          
LC n-3 
PUFA 
food 
(including 
fish oil) 
Men 
and 
women  Iceland 
(Steingrímsd
óttir et al., 
2003)  24-hour recall  1242  15     80  National Icelandic survey  700.0          
n.a.: not available Tolerable Upper Intake Level of EPA, DHA and DPA 
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B.  INTAKE OF LONG-CHAIN N-3 FATTY ACIDS (MG/DAY) AMONG CHILDREN IN EUROPEAN COUNTRIES 
LCn-
3PUFA 
Nutrient 
source  Sex  Country  Reference 
Dietary 
method  n 
Age 
min 
 
Age 
max 
Population / Fortified foods included or 
excluded  mean  median  P75  P95 
EPA  Food 
Boys 
and 
girls  Belgium 
(Sioen et al., 
2007a) 
3-day record 
(food)  661  2.5 
 
6.5 
No consumption of supplements 
containing PUFA. Data collected in 
Flanders.   25.0 
 
21.0 
 
EPA  n.a. 
Boys 
and 
girls  Belgium 
(Sioen et al., 
2007b)  7-day record  341  13     18 
Data collected in the region of Ghent in 
Flanders  55.9  25.4     244.2 
EPA 
Food and 
supplements 
Boys 
and 
girls  Sweden 
(Enghardt 
Barbieri et al., 
2006)  4-day record  590  4     4  National survey  40.0  10.0     140.0 
           
889  8 
 
9  National survey  40.0  20.0 
 
170.0 
                 
1,01
6  11     12  National survey  40.0  20.0     160.0 
DPA  Food 
Boys 
and 
girls  Belgium 
(Sioen et al., 
2007a) 
3-day record 
(food)  661  2.5     6.5 
No consumption of supplements 
containing PUFA. Data collected in 
Flanders.   10.0     10.0    
DPA  n.a. 
Boys 
and 
girls  Belgium 
(Sioen et al., 
2007b)  7-day record  341  13     18 
Data collected in the region of Ghent in 
Flanders  18.4  9.6     62.5 
DPA 
Food and 
supplements 
Boys 
and 
girls  Sweden 
(Enghardt 
Barbieri et al., 
2006)  4-day record  590  4     4  National survey  30.0  20.0     70.0 
                  889  8     9  National survey  40.0  30.0     90.0 
                 
1,01
6  11     12  National survey  40.0  30.0     90.0 
DHA  Food 
Boys 
and 
girls  Belgium 
(Sioen et al., 
2007a) 
3-day record 
(food)  661  2.5 
 
6.5 
No consumption of supplements 
containing PUFA. Data collected in 
Flanders.   47.0 
 
46.0 
 
DHA  n.a. 
Boys 
and 
girls  Belgium 
(Sioen et al., 
2007b)  7-day record  341  13     18 
Data collected in the region of Ghent in 
Flanders  111.4  72.4     363.2 
DHA 
Food and 
supplements 
Boys 
and 
girls  Sweden 
(Enghardt 
Barbieri et al., 
2006)  4-day record  590  4     4  National survey  100.0  60.0     320.0 
           
889  8 
 
9  National survey  120.0  80.0 
 
420.0 
 
              
1,01
6  11     12  National survey  120.0  70.0     420.0 Tolerable Upper Intake Level of EPA, DHA and DPA 
 
43  EFSA Journal 2012;10(7):2815 
LCn-
3PUFA 
Nutrient 
source  Sex  Country  Reference 
Dietary 
method  n 
Age 
min 
 
Age 
max 
Population / Fortified foods included or 
excluded  mean  median  P75  P95 
EPA+ 
DHA  Food  Girls 
The 
Netherlands 
(van Rossum et 
al., 2011) 
2 non-
consecutive 24-
hour dietary 
recalls  151  7     8  National survey     63.0  112.0  243.0 
                  352  9     13  National survey     65.0  119.0  251.0 
                  354  14     18  National survey     69.0  122.0  263.0 
      Boys 
The 
Netherlands 
(van Rossum et 
al., 2011) 
2 non-
consecutive 24-
hour dietary 
recalls  153  7     8  National survey     48.0  88.0  200.0 
                  351  9     13  National survey     56.0  102.0  230.0 
                  352  14     18  National survey     65.0  118.0  263.0 
EPA+ 
DHA  n.a. 
Boys 
and 
girls  Belgium 
(Sioen et al., 
2007b)  7-day record  341  13     18 
Data collected in the region of Ghent in 
Flanders  167.3  96.9     603.0 
EPA+ 
DHA 
Food 
(without 
fortified 
food)  Girls  Germany 
(Sichert-Hellert 
et al., 2009) 
yearly 3-day 
dietary records  241  2  <  4 
fish consumers. Data from the DONALD 
cohort, from 7152 records of 1024 
subjects living in/near Dortmund. Mean 
number of repeated 3-day records: 7.  
In 2717 3-day records, i.e. on 3018 single 
days, fish consumption was documented.  100.0          
                  241  2  <  4 
on days with fish consumption. Data from 
the DONALD cohort  245.0          
                  330  4     6  fish consumers.   135.0          
                  330  4     6  on days with fish consumption.  335.0          
                  294  7     9  fish consumers  181.0          
                  294  7     9  on days with fish consumption  438.0          
                  213  10     12  fish consumers  188.0          
                  213  10     12  on days with fish consumption  473.0          
                  113  13     14  fish consumers  214.0          
                  113  13     14  on days with fish consumption  536.0          
                  132  15     18  fish consumers  264.0          
                  132  15     18  on days with fish consumption  685.0          Tolerable Upper Intake Level of EPA, DHA and DPA 
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LCn-
3PUFA 
Nutrient 
source  Sex  Country  Reference 
Dietary 
method  n 
Age 
min 
 
Age 
max 
Population / Fortified foods included or 
excluded  mean  median  P75  P95 
EPA+ 
DHA 
Food 
(without 
fortified 
food)  Boys  Germany 
(Sichert-Hellert 
et al., 2009) 
yearly 3-day 
dietary records  236  2  <  4 
fish consumers. Data from the DONALD 
cohort, from 7152 records of 1024 
subjects living in/near Dortmund. Mean 
number of repeated 3-day records: 7.  
In 2717 3-day records, i.e. on 3018 single 
days, fish consumption was documented.  118.0          
                  236  2  <  4  on days with fish consumption  289.0          
                  352  4     6  fish consumers  142.0          
                  352  4     6  on days with fish consumption  359.0          
                  306  7     9  fish consumers  168.0          
                  306  7     9  on days with fish consumption  433.0          
           
220  10     12  fish consumers  206.0          
                  220  10     12  on days with fish consumption  528.0          
                  128  13     14  fish consumers  324.0          
                  128  13     14  on days with fish consumption  838.0          
                  152  15     18  fish consumers  301.0          
                  152  15     18  on days with fish consumption  763.0          
EPA+ 
DHA 
Food and 
supplements  Girls 
The 
Netherlands 
(van Rossum et 
al., 2011) 
2 non-
consecutive 24-
hour dietary 
recalls  151  7     8  National survey     66.0  120.0  294.0 
                  352  9     13  National survey     66.0  117.0  264.0 
                  354  14     18  National survey     71.0  126.0  282.0 
EPA+ 
DHA 
Food and 
supplements  Boys 
The 
Netherlands 
(van Rossum et 
al., 2011) 
2 non-
consecutive 24-
hour dietary 
recalls  153  7     8  National survey     62.0  122.0  314.0 
                  351  9     13  National survey     65.0  126.0  317.0 
                  352  14     18  National survey     67.0  124.0  295.0 Tolerable Upper Intake Level of EPA, DHA and DPA 
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LCn-
3PUFA 
Nutrient 
source  Sex  Country  Reference 
Dietary 
method  n 
Age 
min 
 
Age 
max 
Population / Fortified foods included or 
excluded  mean  median  P75  P95 
EPA+ 
DPA+ 
DHA 
Food 
(without 
fortified 
food) 
Boys 
and 
girls  Norway  (VKM, 2011) 
semi-
quantitative 
FFQ 
1,23
1  1     1  National survey. Non breast-fed children.  100.0        400.0 
         
semi-
quantitative 
FFQ 
1,72
0  2 
 
2  National survey  200.0 
   
700.0 
         
4-day record  391  4 
 
4  National survey  200.0 
   
600.0 
         
4-day record  815  9 
 
9  National survey  200.0 
   
700.0 
         
4-day record 
1,00
9  13 
 
13  National survey  200.0        700.0 
EPA+ 
DPA+ 
DHA 
Food and 
supplements 
Boys 
and 
girls  Norway  (VKM, 2011) 
semi-
quantitative 
FFQ 
1,23
1  1     1  National survey. Non breast-fed children.  400.0        1,400.0 
         
semi-
quantitative 
FFQ 
1,72
0  2 
 
2  National survey  600.0 
   
1,700.0 
         
4-day record  391  4 
 
4  National survey  400.0 
   
1,400.0 
         
4-day record  815  9 
 
9  National survey  300.0 
   
1,200.0 
         
4-day record 
1,00
9  13     13  National survey  300.0        1,100.0 
LC n-3 
PUFA 
Food 
(including 
fish oil)  Girls  Iceland 
(Steingrímsdótti
r et al., 2003)  24-hour recall  n.a.  15     19     200.0          
      Boys  Iceland 
(Steingrímsdótti
r et al., 2003)  24-hour recall  n.a.  15     19     400.0          
 
 Tolerable Upper Intake Level of EPA, DHA and DPA 
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C.  INTAKE OF LONG-CHAIN n-3 FATTY ACIDS (% E) AMONG CHILDREN 
LCn-
3PUFA 
Nutrient 
source  Sex  Country  Reference 
Dietary 
method  n 
Age 
min 
Age 
max 
Population / Fortified 
foods included or 
excluded  mean  median  P75  P95 
EPA  Food 
Boys and 
girls  Belgium 
(Sioen et 
al., 2007a) 
3-day 
record 
(food)  661  2.5  6.5 
No consumption of 
supplements containing 
PUFA. Data collected in 
Flanders.   0.02     0.01    
   n.a. 
Boys and 
girls  Belgium 
(Sioen et 
al., 2007b) 
7-day 
record  341  13  18 
Data collected in the 
region of Ghent in 
Flanders  0.02  0.01     0.09 
DPA  Food 
Boys and 
girls  Belgium 
(Sioen et 
al., 2007a) 
3-day 
record 
(food)  661  2.5  6.5 
No consumption of 
supplements containing 
PUFA. Data collected in 
Flanders.   0.01 
 
0.01 
 
 
n.a. 
Boys and 
girls  Belgium 
(Sioen et 
al., 2007b) 
7-day 
record  341  13  18 
Data collected in the 
region of Ghent in 
Flanders  0.01  0 
 
0.03 
DHA  Food 
Boys and 
girls  Belgium 
(Sioen et 
al., 2007a) 
3-day 
record 
(food)  661  2.5  6.5 
No consumption of 
supplements containing 
PUFA. Data collected in 
Flanders.   0.03     0.03    
   n.a. 
Boys and 
girls  Belgium 
(Sioen et 
al., 2007b) 
7-day 
record  341  13  18 
Data collected in the 
region of Ghent in 
Flanders  0.05  0.03     0.15 
EPA+ 
DHA  n.a. 
Boys and 
girls  Belgium 
(Sioen et 
al., 2007b) 
7-day 
record  341  13  18 
Data collected in the 
region of Ghent in 
Flanders  0.07  0.04     0.26 
 
 Tolerable Upper Intake Level of EPA, DHA and DPA 
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GLOSSARY AND ABBREVIATIONS 
AA    Arachidonic acid  
ADHD   Attention-deficit hyperactivity disorder 
ALA    -linoleic acid 
ANSES  Agence  nationale  de  sécurité  sanitaire  de  l'alimentation,  de  l'environnement  et  du 
travail 
ASA    Acetylsalicylic acid 
AT    Antithrombin 
AV    Anisidine value 
BfR    Bundesinstitut fur Risikobewertung 
CHD    Coronary heart disease 
CRP    C-reactive protein 
CSS    Conseil Supérieur de la Santé 
CVD    Cardiovascular disease 
D-A-CH  Deutschland-Austria-Confoederatio Helvetica 
DHA    Docosahexaenoic acid 
DoH    Department of Health 
DPA    Docosapentaenoic acid 
EPA    Eicosapentaenoic acid 
FA    Fatty Acid 
FAO    Food and Agriculture Organization 
FDA    Food and Drug Administration 
GOED    Global Organisation for EPA and DHA Omega-3s 
GRAS    Generally recognised as safe 
HbA1c   Glycated haemoglobin 
HDL    High density lipoprotein 
hs-CRP   High-sensitivity C-reactive Protein 
INR    International normalised ratio Tolerable Upper Intake Level of EPA, DHA and DPA 
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IoM    Institute of Medecine 
LCPUFA  Long chain polyunsaturated fatty acids 
LDL    Low density lipoprotein 
MD    Malondialdehyde 
NNR    Nordic Nutrition Recommendations 
PAI    Plasminogen activator inhibitor 
PAF    Platelet activating factor  
PV    Peroxide value 
PUFA    Polyunsaturated fatty acids  
RCTs    Randomised control trials 
SACN    Scientific Advisory Committee on Nutrition 
SHC    Superior Health Council 
sICAM-1  Soluble intercellular adhesion molecule-1 
TAGs    Triacylglycerols 
TBARS    Thiobarbituric acid reactive substances 
TG    Triglycerides 
TXB2    Thromboxane B2 
TNF-alpha  Tumor necrosis factor-alpha  
t-PA ag   Tissue plasminogen activator antigen 
UL    Tolerable Upper Intake Level 
VCAM-1  Vascular cell adhesion molecule-1 
VKM    Norwegian Scientific Committee for Food Safety 
vWF    von Willebrand factor 
WHO    World Health Organization 